<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">fLs7cLWZKxLGyQhGh9qQZZb</article-id>
      <article-id pub-id-type="other">00004</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000300004</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600304</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011005000007</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Preditores de viabilidade em pacientes com resposta negativa &#224; ecocardiografia de estresse com dobutamina de baixa dose</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Abdel-Salam</surname>
            <given-names>Zainab</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nammas</surname>
            <given-names>Wail</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Cairo</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Ain Shams University</institution>
        <institution content-type="orgdiv1">Faculty of Medicine </institution>
        <institution content-type="orgdiv2">Cardiology Department</institution>
        <country country="EG">Egypt</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>3</issue>
      <fpage>188</fpage>
      <lpage>195</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>02</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>09</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>15</day>
          <month>09</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A ecocardiografia de estresse com dobutamina de baixa dose &#233; um teste espec&#237;fico para predizer disfun&#231;&#227;o de contratilidade revers&#237;vel, mas mesmo assim, sua sensibilidade &#233; menor do que ideal. OBJETIVO: Avaliar os preditores de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o, em pacientes sem viabilidade na ecocardiografia de estresse com dobutamina de baixa dose. M&#201;TODOS: Trinta pacientes consecutivos foram selecionados consecutivamente, que apresentavam estenose coron&#225;ria/oclus&#227;o significantes, trat&#225;veis atrav&#233;s de revasculariza&#231;&#227;o, anormalidade de motilidade de parede regional na distribui&#231;&#227;o da art&#233;ria afetada e aus&#234;ncia de viabilidade na ecocardiografia de estresse com dobutamina de baixa dose. Os pacientes foram submetidos a estudo de imagem com 99mTc-sestamibi em repouso e ent&#227;o submetidos &#224; revasculariza&#231;&#227;o coron&#225;ria bem sucedida. A ecocardiografia de seguimento foi realizada tr&#234;s meses depois. Os pacientes foram classificados em 2 grupos: grupo 1: com evid&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o na ecocardiografia de seguimento e grupo 2: sem evid&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica. Os dois grupos foram comparados em rela&#231;&#227;o aos dados cl&#237;nicos, ecocardiogr&#225;ficos e cintilogr&#225;ficos. RESULTADOS: A m&#233;dia da idade era 52,3 &#177; 5,9 anos e 97% eram do sexo masculino. A porcentagem de capta&#231;&#227;o total de 99mTc-sestamibi foi significantemente mais alta no grupo 1 quando comparado ao grupo 2 (p &lt; 0,01) e foi o preditor independente mais forte de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til no seguimento de 3 meses na an&#225;lise de regress&#227;o multivariada. A curva ROC (Receiver Operating Characteristic) mostrou que um valor de corte da porcentagem de capta&#231;&#227;o total do 99mTc-sestamibi uptake de 72%, foi o melhor preditor da recupera&#231;&#227;o mioc&#225;rdica contr&#225;til, com uma sensibilidade de 100% e especificidade de 95.7%. CONCLUS&#195;O: Em pacientes sem evid&#234;ncia de viabilidade na ecocardiografia de estresse com dobutamina de baixa dose, a porcentagem de capta&#231;&#227;o total do 99mTc-sestamibi prediz, de forma independente, a recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o coron&#225;ria.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Preditores</kwd>
        <kwd>viabilidade</kwd>
        <kwd>revasculariza&#231;&#227;o</kwd>
        <kwd>ecocardiograma de estresse com dobutamina</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>21</day>
        <month>01</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>Preditores de viabilidade em pacientes com resposta negativa &#224; ecocardiografia de estresse com dobutamina de baixa dose</p>
    <p>
      <bold>Zainab Abdel-Salam; Wail Nammas</bold>
    </p>
    <p> Cardiology Department, Faculty of Medicine, Ain Shams University, Cairo - Egito</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A ecocardiografia de estresse com dobutamina de baixa dose &#233; um teste espec&#237;fico para predizer disfun&#231;&#227;o de contratilidade revers&#237;vel, mas mesmo assim, sua sensibilidade &#233; menor do que ideal. </p>
    <p><bold>OBJETIVO: </bold> Avaliar os preditores de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o, em pacientes sem viabilidade na ecocardiografia de estresse com dobutamina de baixa dose. </p>
    <p><bold>M&#201;TODOS:</bold> Trinta pacientes consecutivos foram selecionados consecutivamente, que apresentavam estenose coron&#225;ria/oclus&#227;o significantes, trat&#225;veis atrav&#233;s de revasculariza&#231;&#227;o, anormalidade de motilidade de parede regional na distribui&#231;&#227;o da art&#233;ria afetada e aus&#234;ncia de viabilidade na ecocardiografia de estresse com dobutamina de baixa dose. Os pacientes foram submetidos a estudo de imagem com <sup>99m</sup>Tc-sestamibi em repouso e ent&#227;o submetidos &#224; revasculariza&#231;&#227;o coron&#225;ria bem sucedida. A ecocardiografia de seguimento foi realizada tr&#234;s meses depois. Os pacientes foram classificados em 2 grupos: grupo 1: com evid&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o na ecocardiografia de seguimento e grupo 2: sem evid&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica. Os dois grupos foram comparados em rela&#231;&#227;o aos dados cl&#237;nicos, ecocardiogr&#225;ficos e cintilogr&#225;ficos. </p>
    <p><bold>RESULTADOS:</bold> A m&#233;dia da idade era 52,3 &#177; 5,9 anos e 97% eram do sexo masculino. A porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi foi significantemente mais alta no grupo 1 quando comparado ao grupo 2 (p &lt; 0,01) e foi o preditor independente mais forte de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til no seguimento de 3 meses na an&#225;lise de regress&#227;o multivariada. A curva ROC (<italic>Receiver Operating Characteristic</italic>) mostrou que um valor de corte da porcentagem de capta&#231;&#227;o total do <sup>99m</sup>Tc-sestamibi uptake de 72%, foi o melhor preditor da recupera&#231;&#227;o mioc&#225;rdica contr&#225;til, com uma sensibilidade de 100% e especificidade de 95.7%. </p>
    <p><bold>CONCLUS&#195;O:</bold> Em pacientes sem evid&#234;ncia de viabilidade na ecocardiografia de estresse com dobutamina de baixa dose, a porcentagem de capta&#231;&#227;o total do <sup>99m</sup>Tc-sestamibi prediz, de forma independente, a recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o coron&#225;ria.</p>
    <p><bold>Palavras-chave:</bold> Preditores, viabilidade, revasculariza&#231;&#227;o, ecocardiograma de estresse com dobutamina.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Com o enorme progresso no campo de revasculariza&#231;&#227;o mioc&#225;rdica nas duas &#250;ltimas d&#233;cadas, a predi&#231;&#227;o da presen&#231;a de mioc&#225;rdio vi&#225;vel adquiriu import&#226;ncia cl&#237;nica suprema, particularmente em pacientes considerados para tratamento intervencional<sup>1</sup>. A viabilidade do mioc&#225;rdio representa a defici&#234;ncia da fun&#231;&#227;o contr&#225;til, que &#233; potencialmente revers&#237;vel se o fluxo sangu&#237;neo for restaurado de forma adequada<sup>2</sup>. Presumivelmente, a melhora no suprimento sangu&#237;neo &#224; regi&#245;es disfuncionais, mas vi&#225;veis, resulta em melhora subsequente da fun&#231;&#227;o ventricular esquerda regional e global, melhora nos sintomas de insufici&#234;ncia card&#237;aca (IC), capacidade funcional e sobreviv&#234;ncia de longo prazo. Assim, uma importante considera&#231;&#227;o &#233; se as &#225;reas hipocin&#233;ticas ou acin&#233;ticas representam mioc&#225;rdio vi&#225;vel com suprimento sangu&#237;neo criticamente prejudicado, ou tecido cicatricial necr&#243;tico irreversivelmente danificado<sup>3</sup>. Esse cen&#225;rio tem sido apoiado pelos resultados de v&#225;rios estudos, onde somente pacientes com disfun&#231;&#227;o ventricular esquerda grave, que apresentavam mioc&#225;rdio vi&#225;vel, beneficiavam-se da revasculariza&#231;&#227;o<sup>4</sup>. </p>
    <p>A ecocardiografia sob estresse farmacol&#243;gico tem sido aceita de forma ampla para a identifica&#231;&#227;o de mioc&#225;rdio vi&#225;vel, principalmente devido &#224; sua viabilidade, seguran&#231;a, acur&#225;cia diagn&#243;stica e poder progn&#243;stico<sup>5</sup>. O ecocardiograma de estresse com dobutamina (EED) tem se mostrado um m&#233;todo atraente e cada vez mais utilizado na identifica&#231;&#227;o de mioc&#225;rdio vi&#225;vel, atrav&#233;s de sua capacidade de produzir um aumento na contratilidade mioc&#225;rdica mediado por beta-adrenoreceptor. Descobriu-se que a motilidade de parede em resposta &#224; dobutamina &#233; espec&#237;fico para predizer disfun&#231;&#227;o revers&#237;vel da contratilidade, mas mesmo assim, sua sensibilidade &#233; menor do que a ideal<sup>6</sup>. Em um estudo prospectivo, buscamos explorar os preditores de recupera&#231;&#227;o contr&#225;til ap&#243;s revasculariza&#231;&#227;o, em pacientes com aus&#234;ncia de viabilidade no EED de baixa dose. </p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Sele&#231;&#227;o de pacientes</bold>
    </p>
    <p>Prospectivamente, selecionamos 30 pacientes consecutivos, encaminhados de nossos laborat&#243;rios de cateteriza&#231;&#227;o, com estenose/oclus&#227;o coron&#225;ria significante, no per&#237;odo de Novembro 2006 a Outubro 2008. Os pacientes foram considerados eleg&#237;veis somente se apresentassem anormalidade regional de motilidade de parede na distribui&#231;&#227;o anat&#244;mica das art&#233;rias afetadas como explicado posteriormente, art&#233;rias afetadas trat&#225;veis atrav&#233;s de revasculariza&#231;&#227;o e aus&#234;ncia de viabilidade no EED de baixa dose. Estenose coron&#225;ria significante foi definida como uma obstru&#231;&#227;o m&#237;nima de 70% em pelo menos uma art&#233;ria coron&#225;ria de tamanho consider&#225;vel, (medindo 2,5 mm ou mais em di&#226;metro), vista em dois cortes diferentes. Oclus&#227;o coron&#225;ria total foi definida como obstru&#231;&#227;o luminal de 100% com fluxo TIMI (Thrombolysis In Myocardial Infarction) grau 0 distal ao sitio de obstru&#231;&#227;o. Exclu&#237;mos pacientes com infarto do mioc&#225;rdio recente ou angina inst&#225;vel nas &#250;ltimas 4 semanas, estenose significante da art&#233;ria coron&#225;ria principal esquerda (definida como pelo menos 50% de obstru&#231;&#227;o luminal), IC descompensada, protrus&#227;o de trombo ventricular esquerdo recente, doen&#231;a card&#237;aca valvular ou cong&#234;nita significante, qualquer doen&#231;a mioc&#225;rdica exceto isquemia, fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE) &gt; 40%, bloqueio de ramo, contra-indica&#231;&#227;o ao teste com dobutamina (por exemplo, hist&#243;rico de arritmias ventriculares complexas, hipertens&#227;o n&#227;o-controlada com press&#227;o arterial &gt; 180/110) e pacientes com expectativa de vida limitada devido a doen&#231;a coexistente (por exemplo: malignidade). Antes da inclus&#227;o, o Termo de Consentimento Livre e Informado foi assinado por todos os pacientes, ap&#243;s receberem explica&#231;&#245;es sobre o protocolo do estudo, tipo de dados coletados, forma de processamento dos dados e o escopo da coleta de dados. </p>
    <p>O protocolo do estudo foi revisado e aprovado pelo Comit&#234; Institucional de Pesquisas em Seres Humanos em nosso centro, em conformidade com as diretrizes &#233;ticas da Declara&#231;&#227;o de Helsinki de 1964 e revisadas em 2002. </p>
    <p>
      <bold>Defini&#231;&#245;es dos fatores de risco</bold>
    </p>
    <p>A presen&#231;a de hipertens&#227;o foi definida como press&#227;o arterial sist&#243;lica <underline>&gt;</underline> 140 mmHg e/ou press&#227;o arterial diast&#243;lica <underline>&gt;</underline> 90 mmHg, previamente registrada atrav&#233;s de medidas n&#227;o-invasivas obtidas no consult&#243;rio, que levaram &#224; altera&#231;&#245;es no estilo de vida ou terapia com medicamentos anti-hipertensivos. A presen&#231;a de diabete melito foi definida como n&#237;veis de glicemia de jejum no plasma <underline>&gt;</underline> 126 mg/dl, e/ou n&#237;vel de glicemia 2 horas p&#243;s-carga <underline>&gt;</underline> 200 mg/dl, ou terapia espec&#237;fica medicamentosa anti-diab&#233;tica. Dislipidemia foi definida como n&#237;veis de lipoprote&#237;na de baixa densidade (HDL-c) &gt; 100 mg/dl, e/ou n&#237;veis de triglic&#233;rides s&#233;ricos &gt; 150 mg/dl, e/ou n&#237;veis de lipoprote&#237;na de alta densidade (HDL-c) &lt; 40 mg/dl em homens e &lt; 50 mg/dl em mulheres.</p>
    <p>
      <bold>Avalia&#231;&#227;o ecocardiogr&#225;fica basal</bold>
    </p>
    <p>A avalia&#231;&#227;o da fun&#231;&#227;o sist&#243;lica ventricular esquerda global e regional foi realizada em todos os pacientes atrav&#233;s de ecocardiografia transtor&#225;cica em at&#233; 48 horas ap&#243;s a admiss&#227;o. A ecocardiografia com Doppler foi realizada utilizando-se em equipamento de ultrassom Hewlett Packard Sonos 5500 (Hewlett Packard, Andover, Massachusetts, EUA) equipado com capacidade de imagem harm&#244;nica. Um transdutor de 2,5 MHz foi utilizado para obter imagens padr&#227;o 2D, modo M e Doppler. Os pacientes foram examinados na posi&#231;&#227;o de dec&#250;bito lateral esquerdo, utilizando os cortes padr&#227;o paraesternal e apical. A fun&#231;&#227;o sist&#243;lica ventricular esquerda foi avaliada atrav&#233;s do corte apical de 4 c&#226;maras e 2 c&#226;maras, usando o m&#233;todo de Simpson biplano modificado. A motilidade de parede regional foi avaliada de acordo com o modelo padr&#227;o de 16 segmentos recomendado pela Sociedade Americana de Ecocardiografia<sup>7</sup>. Segmentos individuais foram ent&#227;o sub-agrupados com base na distribui&#231;&#227;o vascular conhecida em territ&#243;rio descendente anterior esquerdo, territ&#243;rio circunflexo esquerdo, territ&#243;rio da art&#233;ria coron&#225;ria direita e segmentos sobrepostos<sup>7</sup>. A motilidade de parede regional foi avaliado visualmente para cada segmento individualmente, considerando ambos a excurs&#227;o endoc&#225;rdica e o espessamento sist&#243;lico e cada segmento foi submetido a gradua&#231;&#227;o de acordo com o sistema de escore semi-quantitativo descrito por Knudsen e cols.<sup>8</sup>. Segmentos com bordas endoc&#225;rdicas mal definidas em 50% ou mais de seu comprimento foram considerados n&#227;o-visualizados e receberam um escore igual a 0<sup>9</sup>. O espessamento de parede foi avaliado &#224; uma dist&#226;ncia de pelo menos 1 cm do segmento adjacente para minimizar o efeito da motilidade de segmentos adjacentes (<italic>tethering</italic>)<sup>10</sup>. A motilidade de parede em um territ&#243;rio vascular foi considerado anormal se o espessamento da parede era anormal em pelo menos dois segmentos n&#227;o-sobrepostos cont&#237;guos<sup>7</sup>. O &#237;ndice do escore de motilidade de parede (IEMP) foi derivado ao dividir-se a soma dos escores dos segmentos individuais pelo n&#250;mero de segmentos interpret&#225;veis. </p>
    <p>
      <bold>Protocolo de estresse ecocardiogr&#225;fico</bold>
    </p>
    <p>Todos os pacientes foram submetidos ao ecocardiograma de estresse com dobutamina (EED) como descrito a seguir: dobutamina (Dobutrex<sup>&#174;</sup>, Lilly, Eli &amp; Cia, Indianapolis, EUA) foi administrada via infus&#227;o intravenosa, com dose inicial de 5 &#181;g/kg/minute, que foi aumentada para 20 &#181;g/kg/minuto, em est&#225;gios de 3 minutos. Os exames foram padronizados e realizados pelo mesmo operador. Os cortes-padr&#227;o foram registrados a n&#237;vel basal e durante cada fase do protocolo de infus&#227;o, bem como durante a recupera&#231;&#227;o. As imagens foram digitalizadas em formato de cine-loop e salvas para avalia&#231;&#227;o e an&#225;lise posteriores. Os cortes foram analisados por um &#250;nico especialista em ecocardiografia (Z. A.), utilizando o software do aparelho de ecocardiografia. A an&#225;lise de viabilidade foi realizada durante todas as fases do protocolo. A avalia&#231;&#227;o visual da motilidade e do espessamento de parede foi realizada como descrita anteriormente. A fun&#231;&#227;o sist&#243;lica ventricular esquerda global e o IEMP foram avaliados em repouso e ao final de cada est&#225;gio. A presen&#231;a de viabilidade foi definida como melhora no escore de motilidade de parede regional de pelo menos 1 grau e em pelo menos dois segmentos n&#227;o-sobrepostos cont&#237;guos, juntamente com uma redu&#231;&#227;o de pelo menos 20% no IEMP global comparado com a avalia&#231;&#227;o basal<sup>10</sup>. O teste de estresse foi realizado com os pacientes recebendo a totalidade de seus medicamentos anti-isqu&#234;micos e anti-insufici&#234;ncia. Todos os pacientes recebiam beta-bloqueadores, inibidores da enzima conversora de angiotensina, estatinas e aspirina. </p>
    <p>
      <bold>Protocolo do estudo de imagem com <sup>99m</sup>Tc-sestamibi</bold>
    </p>
    <p>Os pacientes foram submetidos a estudo de imagem com <sup>99m</sup>Tc-sestamibi, em repouso, com administra&#231;&#227;o de trimetazidina, atrav&#233;s da t&#233;cnica de imagem padr&#227;o, em at&#233; 4 dias ap&#243;s a angiografia coron&#225;ria, contato que nenhum evento isqu&#234;mico tivesse sido registrado no per&#237;odo entre a angiografia coron&#225;ria e o estudo de imagem com <sup>99m</sup>Tc-sestamibi. Trimetazidina (Vastarel<sup>&#174;</sup>, Servier, Fran&#231;a) foi administrada por via oral no dia anterior ao estudo (60 mg dividida em 3 doses iguais de 8 em 8 horas) e 1 hora antes do in&#237;cio da realiza&#231;&#227;o do estudo (60 mg em dose &#250;nica). Uma inje&#231;&#227;o de 25-30 mCi de radiomarcador foi administrada 45-60 minutos antes da aquisi&#231;&#227;o das imagens. As imagens foram adquiridas atrav&#233;s de c&#226;mara gama rotativa tipo detector &#250;nico (GE Starcam 4000i, RU) equipada com colimadores de baixa energia de prop&#243;sito geral. Janelas de energia de 20% foram respectivamente centradas nos picos de 140-keV do <sup>99m</sup>Tc-sestamibi. Trinta e duas imagens foram obtidas em 180&#176;, estendendo-se da proje&#231;&#227;o direita anterior obl&#237;qua de 45&#176; &#224; esquerda posterior obl&#237;qua de 45&#176;. Todos os estudos foram submetidos &#224; verifica&#231;&#245;es de controle de qualidade e corre&#231;&#245;es foram feitas, quando necess&#225;rio, para n&#227;o-uniformidade de c&#226;mera, desvios do centro de rota&#231;&#227;o, movimento do paciente, e o fen&#244;meno de "<italic>upward creep</italic>"<sup>8</sup>.</p>
    <p>
      <bold>An&#225;lise do Estudo de Imagem com<sup> 99m</sup>Tc-sestamibi</bold>
    </p>
    <p>Dois cardiologistas com experi&#234;ncia em cardiologia nuclear, cegados quanto aos dados cl&#237;nicos, ecocardiogr&#225;ficos e angiogr&#225;ficos, analisaram as imagens do estudo com <sup>99m</sup>Tc-sestamibi. A designa&#231;&#227;o vascular dos segmentos mioc&#225;rdicos &#224; distribui&#231;&#227;o vascular das grandes art&#233;rias coron&#225;rias foi realizada de acordo com os sistema de escore de 17 segmentos<sup>11</sup>. A porcentagem de capta&#231;&#227;o de <sup>99m</sup>Tc-sestamibi foi avaliada para cada segmento, individualmente. O valor m&#233;dio da porcentagem de capta&#231;&#227;o de <sup>99m</sup>Tc-sestamibi foi calculado para todos os segmentos ventriculares esquerdos (capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi), bem como separadamente, para cada territ&#243;rio vascular individual. </p>
    <p>
      <bold>Revasculariza&#231;&#227;o coron&#225;ria</bold>
    </p>
    <p>Todos os pacientes foram submetidos &#224; revasculariza&#231;&#227;o coron&#225;ria atrav&#233;s de angioplastia coron&#225;ria percut&#226;nea ou revasculariza&#231;&#227;o do mioc&#225;rdio, de acordo com a decis&#227;o do cl&#237;nico respons&#225;vel. A revasculariza&#231;&#227;o foi realizada em at&#233; 2 semanas ap&#243;s a angiografia coron&#225;ria inicial, contato que nenhum evento isqu&#234;mico tivesse sido reportado no per&#237;odo compreendido entre a angiografia coron&#225;ria e a revasculariza&#231;&#227;o. A decis&#227;o foi baseada na apresenta&#231;&#227;o cl&#237;nica, anatomia coron&#225;ria e evid&#234;ncia de isquemia. </p>
    <p>
      <bold>Seguimento ecocardiogr&#225;fico</bold>
    </p>
    <p>A avalia&#231;&#227;o ecocardiogr&#225;fica de seguimento foi realizada 3 meses ap&#243;s a revasculariza&#231;&#227;o para avaliar a fun&#231;&#227;o sist&#243;lica ventricular esquerda global e regional, como descrito anteriormente. Todas as avalia&#231;&#245;es foram realizadas off-line pelo mesmo ecocardiografista (Z. A.) que estava cegado quanto ao fato de imagens terem sido obtidas antes ou ap&#243;s a revasculariza&#231;&#227;o. A ocorr&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til foi definida como uma melhora no escore de motilidade de parede regional de pelo menos um grau em pelo menos dois segmentos n&#227;o-sobrepostos cont&#237;guos, juntamente com uma redu&#231;&#227;o de pelo menos 20% no IEMP global, quando comparado com a avalia&#231;&#227;o basal<sup>10</sup>. Durante o seguimento, os pacientes foram interrogados quanto &#224; ocorr&#234;ncia de infarto do mioc&#225;rdio ou insufici&#234;ncia card&#237;aca congestiva atrav&#233;s de visitas cl&#237;nicas, contatos telef&#244;nicos, revis&#245;es de prontu&#225;rios m&#233;dicos ou comunica&#231;&#227;o pessoal com o m&#233;dico que fez o encaminhamento. </p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Todas as vari&#225;veis cont&#237;nuas foram apresentadas como m&#233;dia &#177; DP, se apresentassem distribui&#231;&#227;o normal. Os dados foram testados para distribui&#231;&#227;o normal utilizando-se o teste de Kolmogorov-Smirnov. Vari&#225;veis categ&#243;ricas foram descritas com frequ&#234;ncias (porcentagens) absolutas e relativas. De acordo com a defini&#231;&#227;o acima de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til, os pacientes foram classificados em 2 grupos: grupo 1 com evid&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til verdadeira ap&#243;s a revasculariza&#231;&#227;o na ecocardiografia de seguimento; e grupo 2, sem evid&#234;ncia de recupera&#231;&#227;o. Os dois grupos foram comparados em rela&#231;&#227;o &#224;s caracter&#237;sticas cl&#237;nicas, ecocardiogr&#225;ficas, cintilogr&#225;ficas e angiogr&#225;ficas dos pacientes atrav&#233;s do teste <italic>t</italic> n&#227;o-pareado para vari&#225;veis cont&#237;nuas com distribui&#231;&#227;o normal e o teste de Qui-quadrado de Pearson para vari&#225;veis categ&#243;ricas. A an&#225;lise de regress&#227;o multivariada foi realizada para identificar os preditores independentes de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o, na qual a vari&#225;vel dependente era a vari&#225;vel de interesse de desfecho, enquanto os fatores adicionados ao modelo inclu&#237;am o valor m&#233;dio da porcentagem de capta&#231;&#227;o de <sup>99m</sup>Tc-sestamibi por todos os segmentos ventriculares esquerdos (capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi), bem como aquele avaliado separadamente, para cada territ&#243;rio vascular individual, a FEVE m&#233;dia de repouso e o IEMP antes da revasculariza&#231;&#227;o. Eventualmente, uma curva ROC (receiver-operating characteristics) foi gerada para identificar o valor do ponto de corte da porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi que melhor predizia a recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o. O valor de corte ideal foi definido como o valor que resultava na maior &#225;rea sob a curva (AUC). Finalmente, 20 casos foram selecionados ao acaso para an&#225;lise de variabilidade intra-observador. A avalia&#231;&#227;o da variabilidade foi realizada atrav&#233;s de an&#225;lise de regress&#227;o linear. Todas as an&#225;lises foram bilaterais e um valor de probabilidade de P &lt; 0,05 foi considerado estatisticamente significante. As an&#225;lises foram realizadas com o <italic>software</italic> estat&#237;stico SPSS vers&#227;o 12.0 (SPSS Inc., Chicago, IL, EUA). </p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Caracter&#237;sticas demogr&#225;ficas basais</bold>
    </p>
    <p>De um total de 61 pacientes com estenose/oclus&#227;o coron&#225;ria significante, trat&#225;vel por revasculariza&#231;&#227;o e anormalidade de motilidade de parede regional na distribui&#231;&#227;o anat&#244;mica das art&#233;rias afetadas, durante o per&#237;odo do estudo, 31 apresentaram evid&#234;ncia de viabilidade pelo EED de baixa dose, enquanto 30 n&#227;o apresentaram evid&#234;ncia. Todos os pacientes com viabilidade positiva no EED de baixa dose foram submetidos &#224; revasculariza&#231;&#227;o coron&#225;ria. De acordo com a defini&#231;&#227;o anteriormente mencionada de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til na ecocardiografia de seguimento de 3 meses, havia 27 pacientes (87,1%) com evid&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o e 4 (12,9%0 sem evid&#234;ncia de recupera&#231;&#227;o. Um total de 30 pacientes consecutivos sem evid&#234;ncia de viabilidade no EED de baixa dose foi inclu&#237;do no estudo atual, que foram submetidos &#224; revasculariza&#231;&#227;o coron&#225;ria para estenose/oclus&#227;o coron&#225;ria significante. Todos os pacientes completaram o per&#237;odo de seguimento de 3 meses e nenhum paciente relatou qualquer evento cl&#237;nico durante o per&#237;odo da revasculariza&#231;&#227;o &#224; avalia&#231;&#227;o ecocardiogr&#225;fica de seguimento. De acordo com a defini&#231;&#227;o anteriormente mencionada de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til na ecocardiografia de seguimento, havia 7 pacientes (23,3%) com evid&#234;ncia de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o (grupo 1), e 23 (76,7%) sem evid&#234;ncia de recupera&#231;&#227;o (grupo 2). Da amostra total (61 pacientes), o EED de baixa dose predisse a recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o com uma sensibilidade de 79,4% e especificidade de 85,2%<sup>11</sup>. </p>
    <p>A revasculariza&#231;&#227;o foi bem sucedida e completa em todos os pacientes. Todos os pacientes no grupo 1 foram revascularizados atrav&#233;s de revasculariza&#231;&#227;o coron&#225;ria, enquanto no grupo 2, 5 pacientes (21,7%) foram tratados atrav&#233;s de angioplastia coron&#225;ria percut&#226;nea e 18 (78,3%) por revasculariza&#231;&#227;o coron&#225;ria (<italic>p</italic> &gt;0,05). As caracter&#237;sticas demogr&#225;ficas de toda a amostra, bem como dos dois grupos individuais s&#227;o mostradas na <xref ref-type="table" rid="tab01">Tabela 1</xref>. A m&#233;dia da idade era 52,3 &#177; 5,9 anos, e 97% dos pacientes eram do sexo masculino. Diabete melito era mais frequente no grupo 2, em compara&#231;&#227;o com o grupo 1 (69,6% <italic>versus</italic> 28,6% respectivamente, <italic>p</italic> &lt; 0,05). De outro modo, nenhuma diferen&#231;a estatisticamente significante foi encontrada entre os dois grupos, em rela&#231;&#227;o a qualquer caracter&#237;stica demogr&#225;fica. </p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt01.jpg"/></table-wrap>
    <p>
      <bold>Dados ecocardiogr&#225;ficos</bold>
    </p>
    <p>A <xref ref-type="table" rid="tab02">Tabelas 2</xref> mostra os dados do EED de toda a amostra, bem como dos 2 grupos individuais. A n&#237;vel basal, a FEVE m&#233;dia da amostra como um todo era 24 &#177; 4%, enquanto o IEMP m&#233;dio era 2,7 &#177; 0,15. Nenhuma diferen&#231;a estatisticamente significante foi observada entre os dois grupos em rela&#231;&#227;o a qualquer dado do EED (<xref ref-type="table" rid="tab02">Tabelas 2</xref>). No seguimento de 6 meses, a FEVE m&#233;dia era de 30 &#177; 4% <italic>versus</italic> 24 &#177; 4%, enquanto o IEMP m&#233;dio era 2,3 &#177; 0,07 <italic>versus</italic> 2,6 &#177; 0,24, no grupo 1 quando comparado ao grupo 2, respectivamente (<italic>p</italic> &lt; 0,05 para ambos).</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt02.jpg"/></table-wrap>
    <p>O protocolo do EED foi bem tolerado por todos os pacientes, sem grandes efeitos colaterais durante ou ap&#243;s o teste. </p>
    <p>
      <bold>Dados cintilogr&#225;ficos</bold>
    </p>
    <p>A <xref ref-type="table" rid="tab03">Tabelas 3</xref> mostra os dados da cintilografia com <sup>99m</sup>Tc-sestamibi da amostra como um todo, bem como dos dois grupos individuais. A porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi foi significantemente mais alta no grupo 1, quando comparada ao grupo 2 (78 &#177; 3% <italic>versus</italic> 64 &#177; 9% respectivamente, <italic>p</italic> &lt; 0,01). De forma similar, a porcentagem de capta&#231;&#227;o de <sup>99m</sup>Tc-sestamibi pelos segmentos no territ&#243;rio da art&#233;ria coron&#225;ria descendente anterior esquerda foi significantemente mais alta no grupo 1, quando comparado ao grupo 2 (90 &#177; 12% <italic>versus</italic> 78 &#177; 19% respectivamente, <italic>p</italic> &lt; 0,01). </p>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt03.jpg"/></table-wrap>
    <p>
      <bold>Preditores independentes de recupera&#231;&#227;o contr&#225;til</bold>
    </p>
    <p>A an&#225;lise de regress&#227;o multivariada mostrou que a porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi e da capta&#231;&#227;o pelos segmentos no territ&#243;rio da art&#233;ria coron&#225;ria descendente anterior esquerda foram preditores independentes da recupera&#231;&#227;o mioc&#225;rdica contr&#225;til no seguimento de 3 meses ap&#243;s a revasculariza&#231;&#227;o, com o primeiro valor sendo o preditor independente mais forte (<xref ref-type="table" rid="tab04">Tabelas 4</xref>).</p>
    <table-wrap id="tab04">
      <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt04.jpg"/></table-wrap>
    <p>
      <bold>Valor de corte como preditor de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til</bold>
    </p>
    <p>A curva ROC (receiver operating characteristic) revelou que um valor de corte da porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi de 72% foi o melhor preditor de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til aos 3 meses ap&#243;s a revasculariza&#231;&#227;o, com uma &#225;rea sob a curva (AUC) = 0,957 (IC95% = 0,812 a 0,994, <italic>p</italic> &lt; 0,001). Utilizando esse valor de corte de 72%, a porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi apresentou uma sensibilidade de 100% e especificidade de 95,7%, para predizer recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o (<xref ref-type="fig" rid="fig01">Figura 1</xref>).</p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gf01.jpg"/></fig>
    <p>A an&#225;lise de variabilidade intra-observador revelou uma correla&#231;&#227;o pr&#243;xima entre avalia&#231;&#245;es repetidas de motilidade de parede regional por um &#250;nico operador, com um coeficiente de correla&#231;&#227;o r =0,92.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A avalia&#231;&#227;o da viabilidade mioc&#225;rdica &#233; uma das &#225;reas mais desafiantes da cardiologia moderna. O padr&#227;o-ouro para a presen&#231;a de viabilidade &#233; a melhora na contratilidade global e/ou regional ap&#243;s a revasculariza&#231;&#227;o mioc&#225;rdica<sup>12</sup>. Entretanto, a triagem de um paciente para revasculariza&#231;&#227;o depende da consequente "esperada" recupera&#231;&#227;o da fun&#231;&#227;o contr&#225;til na &#225;rea comprometida. Em rela&#231;&#227;o a isso, a capacidade da dobutamina de baixa dose de produzir uma resposta contr&#225;til em segmentos mioc&#225;rdicos disfuncionais, mas vi&#225;veis, que s&#227;o supridos por art&#233;rias com oclus&#227;o ou gravemente estenosadas tem sido uma quest&#227;o controversa. Alguns estudos anteriores relataram a capacidade limitada de at&#233; mesmo doses baixas da dobutamina de revelar a presen&#231;a de mioc&#225;rdio vi&#225;vel na presen&#231;a de estenose coron&#225;ria grave ou oclus&#227;o total, onde o fluxo coron&#225;rio de reserva est&#225; esgotado e a perfus&#227;o mioc&#225;rdica de repouso est&#225; gravemente reduzida<sup>13</sup>. Uma meta-an&#225;lise de seis estudos (287 pacientes) que utilizaram o EED para predizer a melhora da fun&#231;&#227;o sist&#243;lica ventricular esquerda ap&#243;s a revasculariza&#231;&#227;o mostrou sensibilidade e especificidade ponderada m&#233;dia de 57 e 73%, com VPP e VPN de 63 e 68%<sup>14</sup>.</p>
    <p>Altera&#231;&#245;es estruturais complexas ocorrem em mioc&#225;rdio disfuncional vi&#225;vel no n&#237;vel de cardiomi&#243;citos e matriz extracelular<sup>15</sup>, o que inclui anormalidades ultra-estruturais vistas atrav&#233;s de microscopia eletr&#244;nica<sup>16</sup>. Al&#233;m disso, marcadores indiretos de apoptose t&#234;m sido recentemente demonstrados em mais mi&#243;citos card&#237;acos hibernados gravemente comprometidos<sup>17</sup>. Al&#233;m disso, a redu&#231;&#227;o na &#225;rea de jun&#231;&#245;es gap no mioc&#225;rdio hibernado pode interferir com a coordena&#231;&#227;o local da contra&#231;&#227;o mioc&#225;rdica<sup>18</sup>. Outras altera&#231;&#245;es patofisiol&#243;gicas no mioc&#225;rdio disfuncional - mas vi&#225;vel - incluem deple&#231;&#227;o de energia<sup>19</sup> e diminui&#231;&#227;o da responsividade ao c&#225;lcio<sup>20</sup>. De modo geral, eles podem atrapalhar a resposta contr&#225;til &#224; dobutamina de baixa dose, com uma subsequente grande propor&#231;&#227;o de resultados falso-negativos ao EED e uma sensibilidade resultante sub-&#243;tima<sup>6</sup>. </p>
    <p>A quest&#227;o de predi&#231;&#227;o da recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o tem sido controversa por longo tempo. Estudos anteriores na literatura n&#227;o forneceram dados consistentes para determinar os preditores espec&#237;ficos da recupera&#231;&#227;o contr&#225;til potencial. Alguns estudos destacaram a import&#226;ncia das colaterais coron&#225;rias ao territ&#243;rio arterial relacionado ao infarto como um preditor da presen&#231;a de viabilidade mioc&#225;rdica subjacente e potencial recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o<sup>21,22</sup>. Em termos gerais, &#233; sempre recomendado buscar mioc&#225;rdio vi&#225;vel antes da revasculariza&#231;&#227;o de uma art&#233;ria coron&#225;ria oclu&#237;da; entretanto, ainda n&#227;o h&#225; m&#233;todo pr&#225;tico e ao mesmo tempo sens&#237;vel para avaliar a viabilidade mioc&#225;rdica no laborat&#243;rio de cateterismo<sup>21</sup>.</p>
    <p>At&#233; onde sabemos, o presente estudo &#233; o primeiro na literatura em reportar que a porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi, e a porcentagem de capta&#231;&#227;o pelos segmentos no territ&#243;rio da art&#233;ria coron&#225;ria descendente anterior esquerda, foram preditores independentes da "real" recupera&#231;&#227;o mioc&#225;rdica contr&#225;til no seguimento de 3 meses ap&#243;s a revasculariza&#231;&#227;o, em um grupo muito espec&#237;fico de pacientes com aus&#234;ncia de viabilidade no EED de baixa dose. Adicionalmente, um valor de corte de 72% da porcentagem de capta&#231;&#227;o predisse a recupera&#231;&#227;o contr&#225;til, com excelente sensibilidade e especificidade. Entretanto, o presente estudo n&#227;o compara os dois m&#233;todos (EED de baixa dose e estudo de imagem com <sup>99m</sup>Tc-sestamibi) e uma suposta superioridade do estudo de imagem com <sup>99m</sup>Tc-sestamibi sobre o EED de baixa dose n&#227;o pode ser defendida. Al&#233;m disso, mesmo quando a fun&#231;&#227;o sist&#243;lica de repouso n&#227;o mostra recupera&#231;&#227;o ap&#243;s a revasculariza&#231;&#227;o, a presen&#231;a de viabilidade parcial &#233; provavelmente ben&#233;fica para a reserva contr&#225;til, toler&#226;ncia &#224; exerc&#237;cio, preven&#231;&#227;o de remodela&#231;&#227;o e sobreviv&#234;ncia; a revasculariza&#231;&#227;o ainda pode ser ben&#233;fica nesse grupo de pacientes<sup>23</sup>. </p>
    <p>No presente estudo, empregamos um protocolo de estudo de imagem de repouso com <sup>99m</sup>Tc-sestamibi ap&#243;s a administra&#231;&#227;o oral de trimetazidina. </p>
    <p>Evid&#234;ncias s&#243;lidas indicam que o <sup>99m</sup>Tc-sestamibi de repouso pode ser um bom marcador de viabilidade<sup>24-26</sup>. A trimetazidina e o <sup>99m</sup>Tc-sestamibi compartilham o mesmo alvo intracelular: a mitoc&#244;ndria. Como existe reserva metab&#243;lica no estado de hiberna&#231;&#227;o, a trimetazidina pode explorar essa reserva atrav&#233;s do aumento do metabolismo mitocondrial. Um estudo demonstrou que a trimetazidina estava associada com um aumento na capta&#231;&#227;o de <sup>99m</sup>Tc-sestamibi em &#225;reas mioc&#225;rdicas infartadas, mas vi&#225;veis, e declarou que esse aumentou estava provavelmente relacionado &#224; melhora no metabolismo oxidativo mitocondrial, que &#233; essencial para a reten&#231;&#227;o do <sup>99m</sup>Tc-sestamibi. Eles conclu&#237;ram que a associa&#231;&#227;o da administra&#231;&#227;o de trimetazidina com cintilografia de perfus&#227;o com <sup>99m</sup>Tc-sestamibi pode representar uma forma melhor de detec&#231;&#227;o de mioc&#225;rdio vi&#225;vel<sup>27</sup>. </p>
    <p>Nossos resultados sugerem que a aus&#234;ncia de diabete melito tamb&#233;m foi capaz de predizer a presen&#231;a de viabilidade, embora n&#227;o tenha sido um preditor independente na an&#225;lise de regress&#227;o multivariada. Um estudo anterior realizado por Auerbach e cols.<sup>28</sup> relatou que, al&#233;m dos sintomas anginosos, nenhuma rela&#231;&#227;o estatisticamente significante foi encontrada entre a presen&#231;a de viabilidade (detectada pela tomografia de emiss&#227;o de p&#243;sitrons) e qualquer das caracter&#237;sticas cl&#237;nicas, incluindo diabete<sup>28</sup>. Achados inconsistentes refletiriam a natureza heterog&#234;nea da doen&#231;a de base, a falta de uniformidade na sele&#231;&#227;o de pacientes e protocolos de estudo entre os diferentes estudos. </p>
    <p>
      <bold>Limita&#231;&#245;es do estudo</bold>
    </p>
    <p>Nossos achados foram baseados em um &#250;nico centro de estudo com uma amostra relativamente pequena de pacientes, um fato que torna dif&#237;cil generalizar nossos resultados para todos os pacientes sendo submetidos &#224; estratifica&#231;&#227;o de risco a fim de predizer a recupera&#231;&#227;o contr&#225;til ap&#243;s a revasculariza&#231;&#227;o. Estudos multic&#234;ntricos utilizando o mesmo protocolo e com um n&#250;mero maior de pacientes s&#227;o necess&#225;rios. </p>
    <p>Adicionalmente, o n&#250;mero de pacientes que recuperou a contratilidade adequada foi muito pequeno; dessa forma, os resultados do presente estudo deveriam ser considerados com cautela. Al&#233;m disso, o per&#237;odo de seguimento de tr&#234;s meses pode ter sido inadequado para permitir a recupera&#231;&#227;o de alguns segmentos dissin&#233;rgicos, mas vi&#225;veis, o que poderia ser traduzido como uma melhor taxa de recupera&#231;&#227;o mioc&#225;rdica contr&#225;til. O atraso na recupera&#231;&#227;o pode ainda ocorrer em um n&#250;mero significante de segmentos at&#233; uma mediana de 14 meses ap&#243;s a revasculariza&#231;&#227;o, um fato que exige avalia&#231;&#245;es repetidas ap&#243;s per&#237;odos mais longos de seguimento. O fato de que todos os pacientes estavam recebendo beta-bloqueadores antes do teste de estresse com dobutamina pode ter contribu&#237;do para uma propor&#231;&#227;o significante de resultados falso-negativos, j&#225; que &#233; sabido que esse medicamento interfere com a sensibilidade do teste de estresse com dobutamina. Uma poss&#237;vel limita&#231;&#227;o do presente estudo &#233; que ele n&#227;o fornece uma compara&#231;&#227;o direta entre o teste de estresse com dobutamina e a cintilografia de perfus&#227;o com <sup>99m</sup>Tc-sestamibi. Levando em considera&#231;&#227;o o fato que o teste de imagem por resson&#226;ncia magn&#233;tica &#233; considerado o padr&#227;o-ouro para detec&#231;&#227;o de viabilidade, o fato de que os pacientes n&#227;o foram submetidos &#224; essa modalidade de avalia&#231;&#227;o pode constituir outra limita&#231;&#227;o. Outra limita&#231;&#227;o do estudo &#233; a falta de m&#233;todos quantitativos para medir o espessamento sist&#243;lico; ao inv&#233;s disso, o operador adotou apenas a avalia&#231;&#227;o visual. Entretanto, o problema da variabilidade intra-observador pode ser minimizado por forte ader&#234;ncia &#224; padr&#245;es metodol&#243;gicos novos e comuns. </p>
    <p>Finalmente, a angiografia coron&#225;ria de seguimento n&#227;o foi realizada, de forma que re-estenose ou re-oclus&#227;o n&#227;o podem ser exclu&#237;das de forma definitiva, algo que prejudicaria a recupera&#231;&#227;o contr&#225;til inicialmente obtida. Entretanto, nenhum paciente reportou quaisquer eventos cl&#237;nicos durante o per&#237;odo da revasculariza&#231;&#227;o &#224; avalia&#231;&#227;o ecocardiogr&#225;fica de seguimento. </p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Nossos dados sugerem que a recupera&#231;&#227;o mioc&#225;rdica contr&#225;til ap&#243;s a revasculariza&#231;&#227;o em pacientes sem evid&#234;ncia de viabilidade na ecocardiografia de estresse com dobutamina (EED) pode ser prevista de forma independente pela porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi e da capta&#231;&#227;o pelos segmentos no territ&#243;rio da art&#233;ria descendente anterior (ADA) esquerda. Um valor de corte da porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi de 72% foi o melhor preditor da recupera&#231;&#227;o mioc&#225;rdica contr&#225;til tr&#234;s meses ap&#243;s a revasculariza&#231;&#227;o. </p>
    <p>
      <bold>Implica&#231;&#245;es cl&#237;nicas</bold>
    </p>
    <p>Pacientes com disfun&#231;&#227;o ventricular isqu&#234;mica esquerda, cujas art&#233;rias coron&#225;rias s&#227;o trat&#225;veis atrav&#233;s de revasculariza&#231;&#227;o e que n&#227;o apresentam evid&#234;ncia de viabilidade no EED, podem ainda ter alguma esperan&#231;a de obter recupera&#231;&#227;o mioc&#225;rdica contr&#225;til significante ap&#243;s a revasculariza&#231;&#227;o, se apresentarem uma "ampla" porcentagem de capta&#231;&#227;o total de <sup>99m</sup>Tc-sestamibi, especialmente na aus&#234;ncia de diabete melito. O oposto tamb&#233;m &#233; verdade, entretanto: devido &#224; relativamente baixa especificidade da cintigrafia de perfus&#227;o para detectar a viabilidade, o EED pode ser realizado em pacientes com viabilidade positiva atrav&#233;s da cintigrafia de perfus&#227;o. Ainda assim, o uso rotineiro de ambas as modalidade conjuntamente em todos os pacientes n&#227;o pode ser recomendado, pois n&#227;o seria custo-efetivo. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Wail Nammas </p>
        <p> Cardiology Department, Faculty of Medicine, Ain Shams University - Abbassia </p>
        <p> Cairo - Egito - P.O. 11381 </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="wnammas@hotmail.com">wnammas@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 07/02/10; revisado recebido em 15/09/10; aceito em 21/09/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation. 1993;87(1):1-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium</article-title>
          <source>Circulation</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1</fpage>
          <lpage>20</lpage>
          <issue>1</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dilsizian</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Hoffmann R. Stress echocardiography before and after interventional therapy. In: Marwick TH (ed.) Cardiac stress testing and imaging: a clinicians guide. New York: Churchill Livingston; 1996. p. 355-67.</mixed-citation>
        <element-citation publication-type="book">
          <source>Cardiac stress testing and imaging: a clinician's guide</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>355</fpage>
          <lpage>67</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Hoffmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marwick</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Beller GA. Comparison of 201Tl scintigraphy and low-dose dobutamine echocardiography for the noninvasive assessment of myocardial viability. Circulation. 1996;94(11):2712-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of 201Tl scintigraphy and low-dose dobutamine echocardiography for the noninvasive assessment of myocardial viability</article-title>
          <source>Circulation</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>2712</fpage>
          <lpage>9</lpage>
          <issue>11</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Beller</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Jim&#233;nez Borreguero LJ, Ruiz-Salmer&#243;n R. Assessment of myocardial viability in patients before revascularization. Rev Esp Cardiol. 2003;56(7):721-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of myocardial viability in patients before revascularization</article-title>
          <source>Rev Esp Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>721</fpage>
          <lpage>33</lpage>
          <issue>7</issue>
          <volume>56</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jim&#233;nez Borreguero</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Ruiz-Salmer&#243;n</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Marwick TH. Stress echocardiography. Heart. 2003;89(1):113-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Stress echocardiography</article-title>
          <source>Heart</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>113</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Marwick</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Grayburn PA. Defining the threshold of myocardial viability by dobutamine echocardiography. Int J Cardiol. 2003;90(1):31-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Defining the threshold of myocardial viability by dobutamine echocardiography</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>31</fpage>
          <lpage>2</lpage>
          <issue>1</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grayburn</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>358</fpage>
          <lpage>67</lpage>
          <issue>5</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>DeMaria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Feigenbaum</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Knudsen AS, Darwish AZ, N&#248;rgaard A, G&#248;tzsche O, Thygesen K. Time course of myocardial viability after acute myocardial infarction: an echocardiographic study. Am Heart J. 1998;135(1):51-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Time course of myocardial viability after acute myocardial infarction: an echocardiographic study</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>51</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>135</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Knudsen</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Darwish</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>N&#248;rgaard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>G&#248;tzsche</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Thygesen</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Chaudhry FA, Singh B, Galatro K. Reversible left ventricular dysfunction. Echocardiography. 2000;17(5):495-506.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reversible left ventricular dysfunction</article-title>
          <source>Echocardiography</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>495</fpage>
          <lpage>506</lpage>
          <issue>5</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chaudhry</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Galatro</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Meluz&#237;n J, Cern&#253; J, Fr&#233;lich M, Stetka F, Spinarov&#225; L, Popelov&#225; J, et al. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. Investigators of this Multicenter Study. J Am Coll Cardiol. 1998;32(4):912-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction: Investigators of this Multicenter Study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>912</fpage>
          <lpage>20</lpage>
          <issue>4</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Meluz&#237;n</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cern&#253;</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fr&#233;lich</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stetka</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Spinarov&#225;</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Popelov&#225;</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>539</fpage>
          <lpage>42</lpage>
          <issue>4</issue>
          <volume>105</volume>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Hendel RC, Chaudhry FA, Bonow RO. Myocardial viability. Curr Probl Cardiol. 1996;21(3):145-221.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial viability</article-title>
          <source>Curr Probl Cardiol</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>145</fpage>
          <lpage>221</lpage>
          <issue>3</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hendel</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Chaudhry</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Bonow RO. Contractile reserve and coronary blood flow reserve in collateral-dependent myocardium. J Am Coll Cardiol. 1999;33(3):705-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Contractile reserve and coronary blood flow reserve in collateral-dependent myocardium</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>705</fpage>
          <lpage>7</lpage>
          <issue>3</issue>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375-410.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hibernating myocardium: diagnosis and patient outcomes</article-title>
          <source>Curr Probl Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>375</fpage>
          <lpage>410</lpage>
          <issue>7</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schinkel</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Poldermans</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Elhendy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rahimtoola</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Vanoverschelde JL, Wijns W, Borgers M, Heyndrickx G, Depr&#233; C, Flameng W, et al. Chronic myocardial hibernation in humans. From bedside to bench. Circulation. 1997;95(7):1961-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic myocardial hibernation in humans: From bedside to bench</article-title>
          <source>Circulation</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1961</fpage>
          <lpage>71</lpage>
          <issue>7</issue>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vanoverschelde</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Wijns</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Borgers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Heyndrickx</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Depr&#233;</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Flameng</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Ausma J, Cleutjens J, Thon&#233; F, Flameng W, Ramaekers F, Borgers M. Chronic hibernating myocardium: interstitial changes. Mol Cell Biochem. 1995;147(1-2):35-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic hibernating myocardium: interstitial changes</article-title>
          <source>Mol Cell Biochem</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>35</fpage>
          <lpage>42</lpage>
          <issue>1-2</issue>
          <volume>147</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ausma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cleutjens</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thon&#233;</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Flameng</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ramaekers</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Borgers</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Valen G. The basic biology of apoptosis and its implications for cardiac function and viability. Ann Thorac Surg. 2003;75(2):S656-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The basic biology of apoptosis and its implications for cardiac function and viability</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>S656</fpage>
          <lpage>60</lpage>
          <issue>2</issue>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Valen</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Saffitz JE, Yamada KA. Do alterations in intercellular coupling play a role in cardiac contractile dysfunction? Circulation. 1998;97(7):630-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Do alterations in intercellular coupling play a role in cardiac contractile dysfunction</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>630</fpage>
          <lpage>2</lpage>
          <issue>7</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Saffitz</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Els&#228;sser A, M&#252;ller KD, Skwara W, Bode C, K&#252;bler W, Vogt AM. Severe energy deprivation of human hibernating myocardium as possible common pathomechanism of contractile dysfunction, structural degeneration and cell death. J Am Coll Cardiol. 2002;39(7):1189-98.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Severe energy deprivation of human hibernating myocardium as possible common pathomechanism of contractile dysfunction, structural degeneration and cell death</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1189</fpage>
          <lpage>98</lpage>
          <issue>7</issue>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Els&#228;sser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>M&#252;ller</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Skwara</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>K&#252;bler</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Heusch G, Rose J, Skyschally A, Post H, Schulz R. Calcium responsiveness in regional myocardial short-term hibernation and stunning in the in situ porcine heart. Inotropic responses to postextrasystolic potentiation and intracoronary calcium. Circulation. 1996;93(8):1556-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Calcium responsiveness in regional myocardial short-term hibernation and stunning in the in situ porcine heart: Inotropic responses to postextrasystolic potentiation and intracoronary calcium</article-title>
          <source>Circulation</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1556</fpage>
          <lpage>66</lpage>
          <issue>8</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Heusch</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Skyschally</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Post</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Kumbasar D, Aky&#252;rek O, Dincer I, Atmaca Y, Kili&#231;kap M, Erol C, et al. Good collaterals predict viable myocardium. Angiology. 2007;58(5):550-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Good collaterals predict viable myocardium</article-title>
          <source>Angiology</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>550</fpage>
          <lpage>5</lpage>
          <issue>5</issue>
          <volume>58</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kumbasar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aky&#252;rek</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dincer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Atmaca</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kili&#231;kap</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Erol</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Abdel-Salam Z, Nammas W. Predictors of myocardial contractile recovery after coronary revascularization in patients with prior myocardial infarction. Cardiovasc Revasc Med. 2010;11(1):2-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of myocardial contractile recovery after coronary revascularization in patients with prior myocardial infarction</article-title>
          <source>Cardiovasc Revasc Med</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>2</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Abdel-Salam</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Nammas</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Balcells E, Powers ER, Lepper W, Belcik T, Wei K, Ragosta M, et al. Detection of myocardial viability by contrast echocardiography in acute infarction predicts recovery of resting function and contractile reserve. J Am Coll Cardiol. 2003;41(5):827-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Detection of myocardial viability by contrast echocardiography in acute infarction predicts recovery of resting function and contractile reserve</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>827</fpage>
          <lpage>33</lpage>
          <issue>5</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Balcells</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Powers</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Lepper</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Belcik</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ragosta</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Kauffman GJ, Boyne TS, Watson DD, Smith WH, Beller GA. Comparison of rest thallium-201 imaging and rest technetium-99m sestamibi imaging for assessment of myocardial viability in patients with coronary artery disease and severe left ventricular dysfunction. J Am Coll Cardiol. 1996;27(7):1592-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of rest thallium-201 imaging and rest technetium-99m sestamibi imaging for assessment of myocardial viability in patients with coronary artery disease and severe left ventricular dysfunction</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1592</fpage>
          <lpage>7</lpage>
          <issue>7</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kauffman</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Boyne</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Beller</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Dilsizian V, Arrighi JA, Diodati JG, Quyyumi AA, Alavi K, Bacharach SL, et al. Myocardial viability in patients with chronic coronary artery disease: comparison of 99mTc-sestamibi with thallium reinjection and (18F) fluorodeoxyglucose. Circulation. 1994;89(2):578-87.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial viability in patients with chronic coronary artery disease: comparison of 99mTc-sestamibi with thallium reinjection and (18F) fluorodeoxyglucose</article-title>
          <source>Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>578</fpage>
          <lpage>87</lpage>
          <issue>2</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dilsizian</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Arrighi</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Diodati</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Quyyumi</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Alavi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bacharach</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Udelson JE, Coleman PS, Metherall J, Pandian NG, Gomez AR, Griffith JL, et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation. 1994;89(6):2552-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predicting recovery of severe regional ventricular dysfunction: Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi</article-title>
          <source>Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>2552</fpage>
          <lpage>61</lpage>
          <issue>6</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Udelson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Coleman</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Metherall</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pandian</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Griffith</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Ciavolella M, Greco C, Tavolaro R, Tanzilli G, Scopinaro F, Campa PP. Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium. J Nucl Cardiol. 1998;5(2):128-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium</article-title>
          <source>J Nucl Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>128</fpage>
          <lpage>33</lpage>
          <issue>2</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ciavolella</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Greco</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tavolaro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tanzilli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Scopinaro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Campa</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Auerbach MA, Sch&#246;der H, Hoh C, Gambhir SS, Yaghoubi S, Sayre JW, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation. 1999;99(22):2921-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>2921</fpage>
          <lpage>6</lpage>
          <issue>22</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Auerbach</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sch&#246;der</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hoh</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gambhir</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Yaghoubi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sayre</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Predictores de viabilidad en pacientes con respuesta negativa a la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis es un test espec&#237;fico para predecir disfunci&#243;n de contractilidad reversible, pero aun as&#237;, su sensibilidad es menor que lo ideal. OBJETIVO: Evaluar los predictores de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n, en pacientes sin viabilidad en la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis. M&#201;TODOS: Treinta pacientes consecutivos fueron seleccionados consecutivamente, que presentaban estenosis coronaria/oclusi&#243;n significantes, tratables a trav&#233;s de revascularizaci&#243;n, anormalidad de motilidad de pared regional en la distribuci&#243;n de la arteria afectada y ausencia de viabilidad en la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis. Los pacientes fueron sometidos a estudio de imagen con 99mTc-sestamibi en reposo y entonces sometidos a revascularizaci&#243;n coronaria exitosa. La ecocardiograf&#237;a de seguimiento fue realizada tres meses despu&#233;s. Los pacientes fueron clasificados en 2 grupos: grupo 1: con evidencia de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n en la ecocardiograf&#237;a de seguimiento y grupo 2: sin evidencia de recuperaci&#243;n mioc&#225;rdica. Los dos grupos fueron comparados en relaci&#243;n a los datos cl&#237;nicos, ecocardiogr&#225;ficos y de c&#225;mara gamma. RESULTADOS: La media de edad era 52,3 &#177; 5,9 a&#241;os y 97% eran del sexo masculino. El porcentaje de captaci&#243;n total de 99mTc-sestamibi fue significativamente m&#225;s alto en el grupo 1 cuando fue comparado al grupo 2 (p &lt;0,01) y fue el predictor independiente m&#225;s fuerte de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil en el seguimiento de 3 meses en el an&#225;lisis de regresi&#243;n multivariada. La curva ROC (Receiver Operating Characteristic) mostr&#243; que un valor de corte del porcentaje de captaci&#243;n total del 99mTc-sestamibi uptake de 72%, fue el mejor predictor de la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil, con una sensibilidad de 100% y especificidad de 95.7%. CONCLUSI&#211;N: En pacientes sin evidencia de viabilidad en la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis, el porcentaje de captaci&#243;n total del 99mTc-sestamibi predice, de forma independiente, la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n coronaria.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Predictores</kwd>
        <kwd>viabilidad</kwd>
        <kwd>revascularizaci&#243;n</kwd>
        <kwd>ecocardiograma de estr&#233;s con dobutamina</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="enda-body2">
          <label>
            <bold>Predictores de viabilidad en pacientes con respuesta negativa a la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis</bold>
          </label>
          <p>
            <bold>Zainab Abdel-Salam; Wail Nammas </bold>
          </p>
        </fn>
      </p>
      <p>Cardiology Department, Faculty of Medicine, Ain Shams University, Cairo - Egito</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis es un test espec&#237;fico para predecir disfunci&#243;n de contractilidad reversible, pero aun as&#237;, su sensibilidad es menor que lo ideal. </p>
      <p><bold>OBJETIVO:</bold> Evaluar los predictores de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n, en pacientes sin viabilidad en la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis. </p>
      <p><bold>M&#201;TODOS:</bold> Treinta pacientes consecutivos fueron seleccionados consecutivamente, que presentaban estenosis coronaria/oclusi&#243;n significantes, tratables a trav&#233;s de revascularizaci&#243;n, anormalidad de motilidad de pared regional en la distribuci&#243;n de la arteria afectada y ausencia de viabilidad en la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis. Los pacientes fueron sometidos a estudio de imagen con <sup>99m</sup>Tc-sestamibi en reposo y entonces sometidos a revascularizaci&#243;n coronaria exitosa. La ecocardiograf&#237;a de seguimiento fue realizada tres meses despu&#233;s. Los pacientes fueron clasificados en 2 grupos: grupo 1: con evidencia de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n en la ecocardiograf&#237;a de seguimiento y grupo 2: sin evidencia de recuperaci&#243;n mioc&#225;rdica. Los dos grupos fueron comparados en relaci&#243;n a los datos cl&#237;nicos, ecocardiogr&#225;ficos y de c&#225;mara gamma. </p>
      <p><bold>RESULTADOS:</bold> La media de edad era 52,3 &#177; 5,9 a&#241;os y 97% eran del sexo masculino. El porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi fue significativamente m&#225;s alto en el grupo 1 cuando fue comparado al grupo 2 (<italic>p</italic> &lt;0,01) y fue el predictor independiente m&#225;s fuerte de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil en el seguimiento de 3 meses en el an&#225;lisis de regresi&#243;n multivariada. La curva ROC (<italic>Receiver Operating Characteristic</italic>) mostr&#243; que un valor de corte del porcentaje de captaci&#243;n total del 99mTc-sestamibi uptake de 72%, fue el mejor predictor de la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil, con una sensibilidad de 100% y especificidad de 95.7%. </p>
      <p><bold>CONCLUSI&#211;N: </bold>En pacientes sin evidencia de viabilidad en la ecocardiograf&#237;a de estr&#233;s con dobutamina de baja dosis, el porcentaje de captaci&#243;n total del <sup>99m</sup>Tc-sestamibi predice, de forma independiente, la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n coronaria. </p>
      <p><bold>Palabras clave:</bold> Predictores, viabilidad, revascularizaci&#243;n, ecocardiograma de estr&#233;s con dobutamina. </p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>Con el enorme progreso en el campo de revascularizaci&#243;n mioc&#225;rdica en las dos &#250;ltimas d&#233;cadas, la predicci&#243;n de la presencia de miocardio viable adquiri&#243; importancia cl&#237;nica suprema, particularmente en pacientes considerados para tratamiento intervencional<sup>1</sup>. La viabilidad del miocardio representa la deficiencia de la funci&#243;n contr&#225;ctil, que es potencialmente reversible si el flujo sangu&#237;neo fuese restaurado de forma adecuada<sup>2</sup>. Presumiblemente, la mejora en el suministro sangu&#237;neo a las regiones disfuncionales, pero viables, resulta en mejora subsecuente de la funci&#243;n ventricular izquierda regional y global, mejora en los s&#237;ntomas de insuficiencia card&#237;aca (IC), capacidad funcional y supervivencia de largo plazo. As&#237;, una importante consideraci&#243;n es si las &#225;reas hipocin&#233;ticas o acin&#233;ticas representan miocardio viable con suministro sangu&#237;neo cr&#237;ticamente perjudicado, o tejido cicatricial necr&#243;tico irreversiblemente damnificado<sup>3</sup>. Ese escenario ha sido apoyado por los resultados de varios estudios, donde solamente pacientes con disfunci&#243;n ventricular izquierda grave, que presentaban miocardio viable, se beneficiaban de la revascularizaci&#243;n<sup>4</sup>. </p>
      <p>La ecocardiograf&#237;a bajo estr&#233;s farmacol&#243;gico ha sido aceptada de forma amplia para la identificaci&#243;n de miocardio viable, principalmente debido a su viabilidad, seguridad, precisi&#243;n diagn&#243;stica y poder pron&#243;stico<sup>5</sup>. El ecocardiograma de estr&#233;s con dobutamina (EED) se ha mostrado un m&#233;todo atrayente y cada vez m&#225;s utilizado en la identificaci&#243;n de miocardio viable, a trav&#233;s de su capacidad de producir un aumento en la contractilidad mioc&#225;rdica mediado por betabloqueantes adrenoreceptor. Se descubri&#243; que la motilidad de pared en respuesta a la dobutamina es espec&#237;fico para predecir disfunci&#243;n reversible de la contractilidad, pero aun as&#237;, su sensibilidad es menor que la ideal<sup>6</sup>. En un estudio prospectivo, buscamos explotar los predictores de recuperaci&#243;n contr&#225;ctil despu&#233;s de revascularizaci&#243;n, en pacientes con ausencia de viabilidad en el EED de baja dosis. </p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Selecci&#243;n de pacientes</bold>
      </p>
      <p>Prospectivamente, seleccionamos 30 pacientes consecutivos, encaminados de nuestros laboratorios de cateterismo, con estenosis/oclusi&#243;n coronaria significativa, en el per&#237;odo de Noviembre 2006 a Octubre 2008. Los pacientes fueron considerados elegibles solamente se presentasen anormalidad regional de motilidad de pared en la distribuci&#243;n anat&#243;mica de las arterias afectadas como fue explicado posteriormente, arterias afectadas tratables a trav&#233;s de revascularizaci&#243;n y ausencia de viabilidad en el EED de baja dosis. Estenosis coronaria significativa fue definida como una obstrucci&#243;n m&#237;nima de 70% en por lo menos una arteria coronaria de tama&#241;o considerable, (midiendo 2,5 mm o m&#225;s en di&#225;metro), vista en dos cortes diferentes. Oclusi&#243;n coronaria total fue definida como obstrucci&#243;n luminal de 100% con flujo TIMI (<italic>Thrombolysis In Myocardial Infarction</italic>) grado 0 distal al sitio de obstrucci&#243;n. Excluimos pacientes con infarto del miocardio reciente o angina inestable en las &#250;ltimas 4 semanas, estenosis significativa de la arteria coronaria principal izquierda (definida como por lo menos 50% de obstrucci&#243;n luminal), IC descompensada, protrusi&#243;n de trombo ventricular izquierdo reciente, enfermedad card&#237;aca valvular o cong&#233;nita significativa, cualquier enfermedad mioc&#225;rdica excepto isquemia, fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI) &gt; 40%, bloqueo de ramo, contraindicaci&#243;n al test con dobutamina (por ejemplo, historia de arritmias ventriculares complejas, hipertensi&#243;n no controlada con presi&#243;n arterial &gt;180/110) y pacientes con expectativa de vida limitada debido a enfermedad coexistente (por ejemplo: malignidad). Antes de la inclusi&#243;n, el T&#233;rmino de Consentimiento Libre y Informado fue firmado por todos los pacientes, despu&#233;s de recibir explicaciones sobre el protocolo del estudio, tipo de datos colectados, forma de procesamiento de los datos y el objetivo de la colecta de datos. </p>
      <p>El protocolo del estudio fue revisado y aprobado por el Comit&#233; Institucional de Investigaciones en Seres Humanos en nuestro centro, en conformidad con las directrices &#233;ticas de la Declaraci&#243;n de Helsinki de 1964 y revisadas en 2002. </p>
      <p>
        <bold>Definiciones de los factores de riesgo</bold>
      </p>
      <p>La presencia de hipertensi&#243;n fue definida como presi&#243;n arterial sist&#243;lica <underline>&gt;</underline>140 mmHg y/o presi&#243;n arterial diast&#243;lica <underline>&gt;</underline>90 mmHg, previamente registrada a trav&#233;s de medidas no invasivas obtenidas en el consultorio, que llevaron a alteraciones en el estilo de vida o terapia con medicamentos antihipertensivos. La presencia de diabetes mellitus fue definida como niveles de glicemia de ayuno en el plasma <underline>&gt;</underline>126 mg/dl, y/o nivel de glicemia 2 horas post carga <underline>&gt;</underline>200 mg/dl, o terapia espec&#237;fica medicamentosa antidiab&#233;tica. Dislipidemia fue definida como niveles de lipoprote&#237;na de baja densidad (HDL-c) &gt;100 mg/dl, y/o niveles de triglic&#233;ridos s&#233;ricos &gt;150 mg/dl, y/o niveles de lipoprote&#237;na de alta densidad (HDL-c) &lt;40 mg/dl en hombres y &lt;50 mg/dl en mujeres. </p>
      <p>
        <bold>Evaluaci&#243;n ecocardiogr&#225;fica basal</bold>
      </p>
      <p>La evaluaci&#243;n de la funci&#243;n sist&#243;lica ventricular izquierda global y regional fue realizada en todos los pacientes a trav&#233;s de ecocardiograf&#237;a transtor&#225;cica en hasta 48 horas despu&#233;s de la admisi&#243;n. La ecocardiograf&#237;a con Doppler fue realizada utilizando equipamiento de ultrasonido Hewlett Packard Sonos 5500 (Hewlett Packard, Andover, Massachusetts, EUA) equipado con capacidad de imagen arm&#243;nica. Un transductor de 2,5 MHz fue utilizado para obtener im&#225;genes <italic>gold standard</italic> 2D, modo M y Doppler. Los pacientes fueron examinados en la posici&#243;n de dec&#250;bito lateral izquierdo, utilizando los cortes <italic>gold standard</italic> paraesternal y apical. La funci&#243;n sist&#243;lica ventricular izquierda fue evaluada a trav&#233;s del corte apical de 4 c&#225;maras y 2 c&#225;maras, usando el m&#233;todo de Simpson biplano modificado. La motilidad de pared regional fue evaluada de acuerdo con el modelo <italic>gold standard</italic> de 16 segmentos recomendado por la Sociedad Americana de Ecocardiograf&#237;a<sup>7</sup>. Segmentos individuales fueron entonces subagrupados con base en la distribuci&#243;n vascular conocida en territorio descendente anterior izquierdo, territorio circunflejo izquierdo, territorio de la arteria coronaria derecha y segmentos sobrepuestos<sup>7</sup>. La motilidad de pared regional fue evaluado visualmente para cada segmento individualmente, considerando ambos la excursi&#243;n endoc&#225;rdica y el engrosamiento sist&#243;lico y cada segmento fue sometido a grado de acuerdo con el sistema de escore semicuantitativo descripto por Knudsen et al. <sup>8</sup>. Segmentos con bordes endoc&#225;rdicos mal definidos en 50% o m&#225;s de su largo fueron considerados no visualizados y recibieron un escore igual a 0<sup>9</sup>. El engrosamiento de pared fue evaluado a una distancia de por lo menos 1 cm del segmento adyacente para minimizar el efecto de la motilidad de segmentos adyacentes (<italic>tethering</italic>)<sup>10</sup>. La motilidad de pared en un territorio vascular fue considerada anormal si el engrosamiento de la pared era anormal en por lo menos dos segmentos no sobrepuestos contiguos<sup>7</sup>. El &#237;ndice del escore de motilidad de pared (IEMP) fue derivado al dividirse la suma de los escores de los segmentos individuales por el n&#250;mero de segmentos interpretables. </p>
      <p>
        <bold>Protocolo de estr&#233;s ecocardiogr&#225;fico</bold>
      </p>
      <p>Todos los pacientes fueron sometidos a ecocardiograma de estr&#233;s con dobutamina (EED) como es descripto a seguir: dobutamina (Dobutrex<sup>&#174;</sup>, Lilly, Eli &amp; Cia, Indianapolis, EUA) fue administrada v&#237;a infusi&#243;n intravenosa, con dosis inicial de 5 &#181;g/kg/minuto, que fue aumentada a 20 &#181;g/kg/minuto, en niveles de 3 minutos. Los ex&#225;menes fueron estandarizados y realizados por el mismo operador. Los cortes <italic>gold standard</italic> fueron registrados a nivel basal y durante cada fase del protocolo de infusi&#243;n, as&#237; como durante la recuperaci&#243;n. Las im&#225;genes fueron digitalizadas en formato de cine loop y guardadas para evaluaci&#243;n y an&#225;lisis posteriores. Los cortes fueron analizados por un &#250;nico especialista en ecocardiograf&#237;a (Z. A. ), utilizando el software del aparato de ecocardiograf&#237;a. El an&#225;lisis de viabilidad fue realizado durante todas las fases del protocolo. La evaluaci&#243;n visual de la motilidad y del engrosamiento de pared fue realizada como descripta anteriormente. La funci&#243;n sist&#243;lica ventricular izquierda global y el IEMP fueron evaluados en reposo y al final de cada nivel. La presencia de viabilidad fue definida como mejora en el escore de motilidad de pared regional de por lo menos 1 grado y en por lo menos dos segmentos no sobrepuestos contiguos, juntamente con una reducci&#243;n de por lo menos 20% en el IEMP global comparado con la evaluaci&#243;n basal<sup>10</sup>. El test de estr&#233;s fue realizado con los pacientes recibiendo la totalidad de sus medicamentos antiisqu&#233;micos y antiinsuficiencia. Todos los pacientes recib&#237;an betabloqueantes, inhibidores de la enzima conversora de angiotensina, estatinas y aspirina. </p>
      <p>
        <bold>Protocolo del estudio de imagen con <sup>99m</sup>Tc-sestamibi</bold>
      </p>
      <p>Los pacientes fueron sometidos a estudio de imagen con <sup>99m</sup>Tc-sestamibi, en reposo, con administraci&#243;n de trimetazidina, a trav&#233;s de la t&#233;cnica de imagen <italic>gold standard</italic>, en hasta 4 d&#237;as despu&#233;s de la angiograf&#237;a coronaria, contacto que ning&#250;n evento isqu&#233;mico hubiese sido registrado en el per&#237;odo entre la angiografia coronaria y el estudio de imagen con 99mTc-sestamibi. Trimetazidina (Vastarel<sup>&#174;</sup>, Servier, Fran&#231;a) fue administrada por v&#237;a oral el d&#237;a anterior al estudio (60 mg dividida en 3 dosis iguales de 8 en 8 horas) y 1 hora antes del comienzo de la realizaci&#243;n del estudio (60 mg en dosis &#250;nica). Una inyecci&#243;n de 25-30 mCi de radiomarcador fue administrada 45-60 minutos antes de la adquisici&#243;n de las im&#225;genes. Las im&#225;genes fueron adquiridas a trav&#233;s de c&#225;mara gama rotativa tipo detector &#250;nico (GE Starcam 4000i, RU) equipada con colimadores de baja energ&#237;a de prop&#243;sito general. Ventanas de energ&#237;a de 20% fueron respectivamente centradas en los picos de 140-keV del <sup>99m</sup>Tc-sestamibi. Treinta y dos im&#225;genes fueron obtenidas en 180&#186;, extendi&#233;ndose de la proyecci&#243;n derecha anterior oblicua de 45&#186; a la izquierda posterior oblicua de 45&#186;. Todos los estudios fueron sometidos a verificaciones de control de calidad y correcciones fueron hechas, cuando fue necesario, para no uniformidad de c&#225;mara, desv&#237;os del centro de rotaci&#243;n, movimiento del paciente, y el fen&#243;meno de "<italic>upward creep</italic>"<sup>8</sup>. </p>
      <p>
        <bold>An&#225;lisis del estudio de imagen con<sup> 99m</sup>Tc-sestamibi</bold>
      </p>
      <p>Dos cardi&#243;logos con experiencia en cardiolog&#237;a nuclear, ciegos en cuanto a los datos cl&#237;nicos, ecocardiogr&#225;ficos y angiogr&#225;ficos, analizaron las im&#225;genes del estudio con <sup>99m</sup>Tc-sestamibi. La designaci&#243;n vascular de los segmentos mioc&#225;rdicos a la distribuci&#243;n vascular de las grandes arterias coronarias fue realizada de acuerdo con los sistema de escore de 17 segmentos<sup>11</sup>. El porcentaje de captaci&#243;n de <sup>99m</sup>Tc-sestamibi fue evaluado para cada segmento, individualmente. El valor medio del porcentaje de captaci&#243;n de <sup>99m</sup>Tc-sestamibi fue calculado para todos los segmentos ventriculares izquierdos (captaci&#243;n total de <sup>99m</sup>Tc-sestamibi), as&#237; como separadamente, para cada territorio vascular individual. </p>
      <p>
        <bold>Revascularizaci&#243;n coronaria</bold>
      </p>
      <p>Todos los pacientes fueron sometidos a revascularizaci&#243;n coronaria a trav&#233;s de angioplastia coronaria percut&#225;nea o revascularizaci&#243;n del miocardio, de acuerdo con la decisi&#243;n del cl&#237;nico responsable. La revascularizaci&#243;n fue realizada hasta 2 semanas despu&#233;s de la angiografia coronaria inicial, siempre que ning&#250;n evento isqu&#233;mico hubiese sido reportado en el per&#237;odo comprendido entre la angiograf&#237;a coronaria y la revascularizaci&#243;n. La decisi&#243;n fue basada en la presentaci&#243;n cl&#237;nica, anatom&#237;a coronaria y evidencia de isquemia. </p>
      <p>
        <bold>Seguimiento ecocardiogr&#225;fico</bold>
      </p>
      <p>La evaluaci&#243;n ecocardiogr&#225;fica de seguimiento fue realizada 3 meses despu&#233;s de la revascularizaci&#243;n para evaluar la funci&#243;n sist&#243;lica ventricular izquierda global y regional, como descripto anteriormente. Todas las evaluaciones fueron realizadas off-line por el mismo ecocardiografista (Z. A. ) que estaba ciego en cuanto al hecho de que las im&#225;genes hab&#237;an sido obtenidas antes o despu&#233;s de la revascularizaci&#243;n. La ocurrencia de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil fue definida como una mejora en el escore de motilidad de pared regional de por lo menos un grado en por lo menos dos segmentos no sobrepuestos contiguos, juntamente con una reducci&#243;n de por lo menos 20% en el IEMP global, cuando fue comparado con la evaluaci&#243;n basal<sup>10</sup>. Durante el seguimiento, los pacientes fueron interrogados en cuanto a la ocurrencia de infarto de miocardio o insuficiencia card&#237;aca congestiva a trav&#233;s de visitas cl&#237;nicas, contactos telef&#243;nicos, revisiones de historias cl&#237;nicas o comunicaci&#243;n personal con el m&#233;dico que hizo el encaminamiento. </p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Todas las variables continuas fueron presentadas como media &#177; DE, se presentasen distribuci&#243;n normal. Los datos fueron testeados para distribuci&#243;n normal utilizando el test de Kolmogorov-Smirnov. Variables categ&#243;ricas fueron descriptas con frecuencias (porcentajes) absolutas y relativas. De acuerdo con la definici&#243;n encima de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil, los pacientes fueron clasificados en 2 grupos: grupo 1 con evidencia de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil verdadera despu&#233;s de la revascularizaci&#243;n en la ecocardiograf&#237;a de seguimiento; y grupo 2, sin evidencia de recuperaci&#243;n. Los dos grupos fueron comparados en relaci&#243;n a las caracter&#237;sticas cl&#237;nicas, ecocardiogr&#225;ficas, de c&#225;mara gamma y angiogr&#225;ficas de los pacientes a trav&#233;s del test <italic>t</italic> no pareado para variables continuas con distribuci&#243;n normal y el test de Chi-cuadrado de Pearson para variables categ&#243;ricas. El an&#225;lisis de regresi&#243;n multivariada fue realizada para identificar los predictores independientes de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n, en la cual la variable dependiente era la variable de inter&#233;s de desenlace, mientras que los factores adicionados al modelo inclu&#237;an el valor medio del porcentaje de captaci&#243;n de <sup>99m</sup>Tc-sestamibi por todos los segmentos ventriculares izquierdos (captaci&#243;n total de <sup>99m</sup>Tc-sestamibi), as&#237; como aquel evaluado separadamente, para cada territorio vascular individual, la FEVI media de reposo y el IEMP antes de la revascularizaci&#243;n. Eventualmente, una curva ROC (receiver-operating characteristics) fue generada para identificar el valor del punto de corte del porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi que mejor predec&#237;a la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n. El valor de corte ideal fue definido como el valor que resultaba en la mayor &#225;rea bajo la curva (AUC). Finalmente, 20 casos fueron seleccionados al azar para an&#225;lisis de variabilidad intraobservador. La evaluaci&#243;n de la variabilidad fue realizada a trav&#233;s de an&#225;lisis de regresi&#243;n linear. Todos los an&#225;lisis fueron bilaterales y un valor de probabilidad de P&lt;0,05 fue considerado estad&#237;sticamente significativo. Los an&#225;lisis fueron realizados con el software estad&#237;stico SPSS versi&#243;n 12.0 (SPSS Inc. , Chicago, IL, EUA). </p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Caracter&#237;sticas demogr&#225;ficas basales</bold>
      </p>
      <p>De un total de 61 pacientes con estenosis/oclusi&#243;n coronaria significativa, tratable por revascularizaci&#243;n y anormalidad de motilidad de pared regional en la distribuci&#243;n anat&#243;mica de las arterias afectadas, durante el per&#237;odo del estudio, 31 presentaron evidencia de viabilidad por el EED de baja dosis, mientras que 30 no presentaron evidencia. Todos los pacientes con viabilidad positiva en el EED de baja dosis fueron sometidos a revascularizaci&#243;n coronaria. De acuerdo con la definici&#243;n anteriormente mencionada de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil en la ecocardiograf&#237;a de seguimiento de 3 meses, hab&#237;a 27 pacientes (87,1%) con evidencia de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n y 4 (12,9%0 sin evidencia de recuperaci&#243;n. Un total de 30 pacientes consecutivos sin evidencia de viabilidad en el EED de baja dosis fue incluido en el estudio actual, que fueron sometidos a revascularizaci&#243;n coronaria para estenosis/oclusi&#243;n coronaria significativa. Todos los pacientes completaron el per&#237;odo de seguimiento de 3 meses y ning&#250;n paciente relat&#243; alg&#250;n evento cl&#237;nico durante el per&#237;odo de la revascularizaci&#243;n a la evaluaci&#243;n ecocardiogr&#225;fica de seguimiento. De acuerdo con la definici&#243;n anteriormente mencionada de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil en la ecocardiograf&#237;a de seguimiento, hab&#237;a 7 pacientes (23,3%) con evidencia de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n (grupo 1), y 23 (76,7%) sin evidencia de recuperaci&#243;n (grupo 2). De la muestra total (61 pacientes), el EED de baja dosis predijo la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n con una sensibilidad de 79,4% y especificidad de 85,2%<sup>11</sup>. </p>
      <p>La revascularizaci&#243;n fue exitosa y completa en todos los pacientes. Todos los pacientes en el grupo 1 fueron revascularizados a trav&#233;s de revascularizaci&#243;n coronaria, mientras que en el grupo 2, 5 pacientes (21,7%) fueron tratados a trav&#233;s de angioplastia coronaria percut&#225;nea y 18 (78,3%) por revascularizaci&#243;n coronaria (<italic>p</italic> &gt;0,05). Las caracter&#237;sticas demogr&#225;ficas de toda la muestra, as&#237; como de los dos grupos individuales son mostradas en la <xref ref-type="table" rid="tab1-body2">Tabla 1</xref>. La media de la edad era 52,3 &#177; 5,9 a&#241;os, y 97% de los pacientes eran del sexo masculino. Diabetes mellitus era m&#225;s frecuente en el grupo 2, en comparaci&#243;n con el grupo 1 (69,6% <italic>vs</italic> 28,6% respectivamente, <italic>p</italic> &lt;0,05). De otro modo, ninguna diferencia estad&#237;sticamente significativa fue encontrada entre los dos grupos, en relaci&#243;n a cualquier caracter&#237;stica demogr&#225;fica. </p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt01-es.jpg"/></table-wrap>
      <p>
        <bold>Datos ecocardiogr&#225;ficos</bold>
      </p>
      <p>La <xref ref-type="table" rid="tab2-body2">Tabla 2</xref> muestra los datos del EED de toda la muestra, as&#237; como de los 2 grupos individuales. A nivel basal, la FEVI media de la muestra como un todo era 24 &#177; 4%, mientras que el IEMP medio era 2,7 &#177; 0,15. Ninguna diferencia estad&#237;sticamente significativa fue observada entre los dos grupos en relaci&#243;n a cualquier dado del EED (<xref ref-type="table" rid="tab2-body2">Tabla 2</xref>). En el seguimiento de 6 meses, la FEVI media era de 30 &#177; 4% <italic>vs</italic> 24 &#177; 4%, mientras que el IEMP medio era 2,3 &#177; 0,07 <italic>vs</italic> 2,6 &#177; 0,24, en el grupo 1 cuando fue comparado al grupo 2, respectivamente (<italic>p</italic> &lt;0,05 para ambos). </p>
      <table-wrap id="tab2-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt02-es.jpg"/></table-wrap>
      <p>El protocolo del EED fue bien tolerado por todos los pacientes, sin grandes efectos colaterales durante o despu&#233;s del test. </p>
      <p>
        <bold>Datos de c&#225;mara gamma </bold>
      </p>
      <p>La <xref ref-type="table" rid="tab3-body2">Tabla 3</xref> muestra los datos de la c&#225;mara gamma con <sup>99m</sup>Tc-sestamibi de la muestra como un todo, bien como de los dos grupos individuales. El porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi fue significativamente m&#225;s alta en el grupo 1, cuando fue comparada al grupo 2 (78 &#177; 3% <italic>vs</italic> 64 &#177; 9% respectivamente, <italic>p</italic> &lt;0,01). De forma similar, el porcentaje de captaci&#243;n de <sup>99m</sup>Tc-sestamibi por los segmentos en el territorio de la arteria coronaria descendente anterior izquierda fue significativamente m&#225;s alta en el grupo 1, cuando fue comparado al grupo 2 (90 &#177; 12% <italic>vs</italic> 78 &#177; 19% respectivamente, <italic>p</italic> &lt;0,01). </p>
      <table-wrap id="tab3-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt03-es.jpg"/></table-wrap>
      <p>
        <bold>Predictores independientes de recuperaci&#243;n contr&#225;ctil</bold>
      </p>
      <p>El an&#225;lisis de regresi&#243;n multivariada mostr&#243; que el porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi y de la captaci&#243;n por los segmentos en el territorio de la arteria coronaria descendente anterior izquierda fueron predictores independientes de la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil en seguimiento de 3 meses despu&#233;s de la revascularizaci&#243;n, con el primero valor siendo el predictor independiente m&#225;s fuerte (<xref ref-type="table" rid="tab4-body2">Tabla 4</xref>). </p>
      <table-wrap id="tab4-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt04-es.jpg"/></table-wrap>
      <p>
        <bold>Valor de corte como predictor de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil</bold>
      </p>
      <p>La curva ROC (receiver operating characteristic) revel&#243; que un valor de corte del porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi de 72% fue el mejor predictor de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil a los 3 meses despu&#233;s de la revascularizaci&#243;n, con una &#225;rea bajo la curva (AUC) = 0,957 (IC95% = 0,812 la 0,994, <italic>p</italic> &lt;0,001). Utilizando ese valor de corte de 72%, el porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi present&#243; una sensibilidad de 100% y especificidad de 95,7%, para predecir recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n (<xref ref-type="fig" rid="fig1-body2">Figura 1</xref>). </p>
      <fig id="fig1-body2">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gf01-es.jpg"/></fig>
      <p>El an&#225;lisis de variabilidad intraobservador revel&#243; una correlaci&#243;n pr&#243;xima entre evaluaciones repetidas de motilidad de pared regional por un &#250;nico operador, con un coeficiente de correlaci&#243;n r =0,92. </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La evaluaci&#243;n de la viabilidad mioc&#225;rdica es una de las &#225;reas m&#225;s desafiantes de la cardiolog&#237;a moderna. El <italic>gold standard</italic> para la presencia de viabilidad es la mejora en la contractilidad global y/o regional despu&#233;s de la revascularizaci&#243;n mioc&#225;rdica<sup>12</sup>. Entre tanto, la elecci&#243;n de un paciente para revascularizaci&#243;n depende de la consecuente "esperada" recuperaci&#243;n de la funci&#243;n contr&#225;ctil en el &#225;rea comprometida. En relaci&#243;n a eso, la capacidad de la dobutamina de baja dosis de producir una respuesta contr&#225;ctil en segmentos mioc&#225;rdicos disfuncionales, pero viables, que son irrigados por arterias con oclusi&#243;n o gravemente estenosadas han sido una cuesti&#243;n controvertida. Algunos estudios anteriores relataron la capacidad limitada de hasta aun dosis bajas de dobutamina de revelar la presencia de miocardio viable en presencia de estenosis coronaria grave o oclusi&#243;n total, donde el flujo coronario de reserva est&#225; agotado y la perfusi&#243;n mioc&#225;rdica de reposo est&#225; gravemente reducida<sup>13</sup>. Un metan&#225;lisis de seis estudios (287 pacientes) que utilizaron el EED para predecir la mejora de la funci&#243;n sist&#243;lica ventricular izquierda despu&#233;s de revascularizaci&#243;n mostr&#243; sensibilidad y especificidad ponderada media de 57 y 73%, con VPP y VPN de 63 y 68%<sup>14</sup>. </p>
      <p>Alteraciones estructurales complejas ocurren en miocardio disfuncional viable a nivel de cardiomiocitos y matriz extracelular<sup>15</sup>, lo que incluye anormalidades ultraestructurales vistas a trav&#233;s de microscopia electr&#243;nica<sup>16</sup>. Adem&#225;s de eso, marcadores indirectos de apoptosis han sido recientemente demostrados en m&#225;s mocitos card&#237;acos hibernados gravemente comprometidos<sup>17</sup>. Adem&#225;s de eso, la reducci&#243;n en la &#225;rea de junciones gap en el miocardio hibernado puede interferir con la coordinaci&#243;n local de la contracci&#243;n mioc&#225;rdica<sup>18</sup>. Otras alteraciones patofisiol&#243;gicas en el miocardio disfuncional - pero viable - incluyen depleci&#243;n de energia<sup>19</sup> y disminuci&#243;n de la responsividad al calcio<sup>20</sup>. De modo general, pueden dificultar la respuesta contr&#225;ctil a la dobutamina de baja dosis, con una subsecuente gran proporci&#243;n de resultados falso negativos al EED y una sensibilidad resultante sub &#243;tima<sup>6</sup>. </p>
      <p>La cuesti&#243;n de predicci&#243;n de la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n han sido controvertida por largo tiempo. Estudios anteriores en la literatura no proveyeron datos consistentes para determinar los predictores espec&#237;ficos de la recuperaci&#243;n contr&#225;ctil potencial. Algunos estudios destacaron la importancia de las colaterales coronarias al territorio arterial relacionado al infarto como un predictor de la presencia de viabilidad mioc&#225;rdica subyacente y potencial recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n<sup>21,22</sup>. En t&#233;rminos generales, es siempre recomendado buscar miocardio viable antes de la revascularizaci&#243;n de una arteria coronaria ocluida; entre tanto, aun no hay m&#233;todo pr&#225;ctico y al mismo tiempo sensible para evaluar la viabilidad mioc&#225;rdica en el laboratorio de cateterismo<sup>21</sup>. </p>
      <p>Hasta donde sabemos, el presente estudio es el primero en la literatura en reportar que el porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi, y el porcentaje de captaci&#243;n por los segmentos en el territorio de la arteria coronaria descendente anterior izquierda, fueron predictores independientes de la "real" recuperaci&#243;n mioc&#225;rdica contr&#225;ctil en el seguimiento de 3 meses despu&#233;s de la revascularizaci&#243;n, en un grupo muy espec&#237;fico de pacientes con ausencia de viabilidad en el EED de baja dosis. Adicionalmente, un valor de corte de 72% del porcentaje de captaci&#243;n predijo la recuperaci&#243;n contr&#225;ctil, con excelente sensibilidad y especificidad. Entre tanto, el presente estudio no compara los dos m&#233;todos (EED de baja dosis y estudio de imagen con <sup>99m</sup>Tc-sestamibi) y una supuesta superioridad del estudio de imagen con <sup>99m</sup>Tc-sestamibi sobre el EED de baja dosis no puede ser defendida. Adem&#225;s de eso, aun cuando la funci&#243;n sist&#243;lica de reposo no muestra recuperaci&#243;n despu&#233;s de la revascularizaci&#243;n, la presencia de viabilidad parcial es probablemente ben&#233;fica para la reserva contr&#225;ctil, tolerancia al ejercicio, prevenci&#243;n de remodelaci&#243;n y supervivencia; la revascularizaci&#243;n aun puede ser ben&#233;fica en ese grupo de pacientes<sup>23</sup>. </p>
      <p>En el presente estudio, empleamos un protocolo de estudio de imagen de reposo con <sup>99m</sup>Tc-sestamibi despu&#233;s de la administraci&#243;n oral de trimetazidina. </p>
      <p>Evidencias s&#243;lidas indican que el <sup>99m</sup>Tc-sestamibi de reposo puede ser un buen marcador de viabilidade<sup>24-26</sup>. La trimetazidina y el <sup>99m</sup>Tc-sestamibi comparten el mismo blanco intracelular: la mitocondria. Como existe reserva metab&#243;lica en el estado de hibernaci&#243;n, la trimetazidina puede explotar esa reserva a trav&#233;s del aumento del metabolismo mitocondrial. Un estudio demostr&#243; que la trimetazidina estaba asociada con un aumento en la captaci&#243;n de <sup>99m</sup>Tc-sestamibi en &#225;reas mioc&#225;rdicas infartadas, pero viables, y declar&#243; que ese aument&#243; estaba probablemente relacionado a la mejora en el metabolismo oxidativo mitocondrial, que es esencial para la retenci&#243;n del <sup>99m</sup>Tc-sestamibi. Concluyeron que la asociaci&#243;n de la administraci&#243;n de trimetazidina con c&#225;mara gamma de perfusi&#243;n con <sup>99m</sup>Tc-sestamibi puede representar una forma mejor de detecci&#243;n de miocardio viable<sup>27</sup>. </p>
      <p>Nuestros resultados sugieren que la ausencia de diabetes mellitus tambi&#233;n fue capaz de predecir la presencia de viabilidad, aunque no haya sido un predictor independiente en el an&#225;lisis de regresi&#243;n multivariada. Un estudio anterior realizado por Auerbach et al. <sup>28</sup> relat&#243; que, adem&#225;s de los s&#237;ntomas anginosos, ninguna relaci&#243;n estad&#237;sticamente significativa fue encontrada entre la presencia de viabilidad (detectada por la tomograf&#237;a de emisi&#243;n de positrones) y cualquiera de las caracter&#237;sticas cl&#237;nicas, incluyendo diabetes<sup>28</sup>. Hallazgos inconsistentes reflejaron la naturaleza heterog&#233;nea de la enfermedad de base, la falta de uniformidad en la selecci&#243;n de pacientes y protocolos de estudio entre los diferentes estudios. </p>
      <p>
        <bold>Limitaciones del estudio</bold>
      </p>
      <p>Nuestros hallazgos fueron basados en un &#250;nico centro de estudio con una muestra relativamente peque&#241;a de pacientes, un hecho que vuelve dif&#237;cil generalizar nuestros resultados para todos los pacientes que son sometidos a la estratificaci&#243;n de riesgo a fin de predecir la recuperaci&#243;n contr&#225;ctil despu&#233;s de la revascularizaci&#243;n. Estudios multic&#233;ntricos utilizando el mismo protocolo y con un n&#250;mero mayor de pacientes son necesarios. </p>
      <p>Adicionalmente, el n&#250;mero de pacientes que recuper&#243; la contractilidad adecuada fue muy peque&#241;o; de esa forma, los resultados del presente estudio deber&#237;an ser considerados con cautela. Adem&#225;s de eso, el per&#237;odo de seguimiento de tres meses puede haber sido inadecuado para permitir la recuperaci&#243;n de algunos segmentos disin&#233;rgicos, pero viables, lo que podr&#237;a ser traducido como una mejor tasa de recuperaci&#243;n mioc&#225;rdica contr&#225;ctil. El atraso en la recuperaci&#243;n puede aun ocurrir en un n&#250;mero significativo de segmentos hasta una mediana de 14 meses despu&#233;s de la revascularizaci&#243;n, un hecho que exige evaluaciones repetidas despu&#233;s de per&#237;odos m&#225;s largos de seguimiento. El hecho de que todos los pacientes estaban recibiendo betabloqueantes antes del test de estr&#233;s con dobutamina puede haber contribuido a una proporci&#243;n significativa de resultados falso negativos, ya que es sabido que ese medicamento interfiere en la sensibilidad del test de estr&#233;s con dobutamina. Una posible limitaci&#243;n del presente estudio es que no provee una comparaci&#243;n directa entre el test de estr&#233;s con dobutamina y la c&#225;mara gamma de perfusi&#243;n con <sup>99m</sup>Tc-sestamibi. Llevando en consideraci&#243;n el hecho que el test de imagen por resonancia magn&#233;tica es considerado el <italic>gold standard</italic> para detecci&#243;n de viabilidad, el hecho de que los pacientes no fueron sometidos a esa modalidad de evaluaci&#243;n puede constituir otra limitaci&#243;n. Otra limitaci&#243;n del estudio es la falta de m&#233;todos cuantitativos para medir el engrosamiento sist&#243;lico; al rev&#233;s de eso, el operador adopt&#243; apenas la evaluaci&#243;n visual. Entre tanto, el problema de la variabilidad intraobservador puede ser minimizado por fuerte adherencia a est&#225;ndares metodol&#243;gicos nuevos y comunes. </p>
      <p>Finalmente, la angiograf&#237;a coronaria de seguimiento no fue realizada, de forma que reestenosis o reoclusi&#243;n no pueden ser excluidas de forma definitiva, algo que perjudicar&#237;a la recuperaci&#243;n contr&#225;ctil inicialmente obtenida. Entre tanto, ning&#250;n paciente report&#243; evento cl&#237;nico alguno durante el per&#237;odo de la revascularizaci&#243;n a la evaluaci&#243;n ecocardiogr&#225;fica de seguimiento. </p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Nuestros datos sugieren que la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil despu&#233;s de la revascularizaci&#243;n en pacientes sin evidencia de viabilidad en la ecocardiograf&#237;a de estr&#233;s con dobutamina (EED) puede ser prevista de forma independiente por el porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi y de la captaci&#243;n por los segmentos en el territorio de la arteria descendente anterior (ADA) izquierda. Un valor de corte del porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi de 72% fue el mejor predictor de la recuperaci&#243;n mioc&#225;rdica contr&#225;ctil tres meses despu&#233;s de la revascularizaci&#243;n. </p>
      <p>
        <bold>Implicaciones Cl&#237;nicas</bold>
      </p>
      <p>Pacientes con disfunci&#243;n ventricular isqu&#233;mica izquierda, cuyas arterias coronarias son tratables a trav&#233;s de revascularizaci&#243;n y que no presentan evidencia de viabilidad en el EED, pueden aun tener alguna esperanza de obtener recuperaci&#243;n mioc&#225;rdica contr&#225;ctil significativa despu&#233;s de la revascularizaci&#243;n, si presentan un "amplio" porcentaje de captaci&#243;n total de <sup>99m</sup>Tc-sestamibi, especialmente en la ausencia de diabetes mellitus. Lo opuesto tambi&#233;n es verdad, entre tanto: debido a la relativamente baja especificidad de la c&#225;mara gamma de perfusi&#243;n para detectar la viabilidad, el EED puede ser realizado en pacientes con viabilidad positiva a trav&#233;s de la c&#225;mara gamma de perfusi&#243;n. Aun as&#237;, el uso rutinario de ambas modalidades conjuntamente en todos los pacientes no puede ser recomendado, pues no ser&#237;a costo-efectivo. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes. </p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiamiento externas. </p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado. </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Predictors of viability in patients with negative low-dose dobutamine stress echocardiograph</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Low-dose dobutamine stress echocardiography is specific for predicting reversible contractility dysfunction, but its sensitivity is lower than ideal. OBJECTIVE: We sought to explore the predictors of myocardial contractile recovery following revascularization, in patients with no viability by low-dose dobutamine stress echocardiography. METHODS: We prospectively enrolled 30 consecutive patients with significant coronary stenosis/occlusion amenable for revascularization, regional wall motion abnormality in the distribution of the affected artery and absence of viability by low-dose dobutamine stress echocardiography. They underwent resting 99mTc-sestamibi imaging study, and then underwent successful coronary revascularization. Follow-up echocardiography was performed 3 months later. Patients were classified into 2 groups: group 1: with evidence of myocardial contractile recovery after revascularization at follow-up echocardiography and group 2: with no such evidence of recovery. The two groups were compared with respect to patients&#8217; clinical, echocardiographic and scintigraphic data. RESULTS: The mean age was 52.3 &#177; 5.9 years, with 97% being males. The percentage of total 99mTc-sestamibi uptake was significantly higher in group 1 as compared to group 2 (p &lt; 0.01), and it was the strongest independent predictor of myocardial contractile recovery at 3-month follow-up by multivariate regression analysis. Receiver operating characteristics curve revealed that a cutoff value of the percentage of total 99mTc-sestamibi uptake of 72% best predicted myocardial contractile recovery, with a sensitivity of 100% and specificity of 95.7%. CONCLUSION: In patients with no viability by low-dose dobutamine stress echocardiography, the percentage of total 99mTc-sestamibi uptake independently predicted myocardial contractile recovery following coronary revascularization.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Predictors</kwd>
        <kwd>viability</kwd>
        <kwd>revascularization</kwd>
        <kwd>dobutamine stress echocardiography</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p><undefined id="tx-body3"/>Predictors of viability in patients with negative low-dose dobutamine stress echocardiograph</p>
      <p>
        <bold>Zainab Abdel-Salam and Wail Nammas</bold>
      </p>
      <p> Cardiology Department, Faculty of Medicine, Ain Shams University, Cairo - Egypt</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Low-dose dobutamine stress echocardiography is specific for predicting reversible contractility dysfunction, but its sensitivity is lower than ideal.</p>
      <p><bold>OBJECTIVE:</bold> We sought to explore the predictors of myocardial contractile recovery following revascularization, in patients with no viability by low-dose dobutamine stress echocardiography.</p>
      <p><bold>METHODS:</bold> We prospectively enrolled 30 consecutive patients with significant coronary stenosis/occlusion amenable for revascularization, regional wall motion abnormality in the distribution of the affected artery and absence of viability by low-dose dobutamine stress echocardiography. They underwent resting <sup>99m</sup>Tc-sestamibi imaging study, and then underwent successful coronary revascularization. Follow-up echocardiography was performed 3 months later. Patients were classified into 2 groups: group 1: with evidence of myocardial contractile recovery after revascularization at follow-up echocardiography and group 2: with no such evidence of recovery. The two groups were compared with respect to patients&#146; clinical, echocardiographic and scintigraphic data.</p>
      <p><bold>RESULTS:</bold> The mean age was 52.3 &#177; 5.9 years, with 97% being males. The percentage of total <sup>99m</sup>Tc-sestamibi uptake was significantly higher in group 1 as compared to group 2 (p &lt; 0.01), and it was the strongest independent predictor of myocardial contractile recovery at 3-month follow-up by multivariate regression analysis. Receiver operating characteristics curve revealed that a cutoff value of the percentage of total <sup>99m</sup>Tc-sestamibi uptake of 72% best predicted myocardial contractile recovery, with a sensitivity of 100% and specificity of 95.7%.</p>
      <p><bold>CONCLUSION:</bold> In patients with no viability by low-dose dobutamine stress echocardiography, the percentage of total <sup>99m</sup>Tc-sestamibi uptake independently predicted myocardial contractile recovery following coronary revascularization.</p>
      <p><bold>Keywords:</bold> Predictors; viability; revascularization; dobutamine stress echocardiography.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>With the enormous progress in the field of myocardial revascularization over the last two decades, predicting the presence of viable myocardium has acquired paramount clinical importance, particularly in patients considered for interventional treatment<sup>1</sup>. Myocardial viability represents the impairment of contractile function that is potentially reversible if blood supply is adequately restored<sup>2</sup>. Presumably, improving blood supply to dysfunctional, but viable regions, results in subsequent improvement in regional and global left ventricular function, heart failure symptoms, functional capacity and long-term survival. Thus, an important consideration is whether hypokinetic or akinetic myocardial areas represent viable myocardium with critically endangered blood supply, or irreversibly damaged necrotic scar tissue<sup>3</sup>. This scenario was supported by the results of several studies, wherein only patients with severe left ventricular dysfunction who harbored viable myocardium, benefited from revascularization<sup>4</sup>. </p>
      <p>Pharmacological stress echocardiography has gained wide acceptance for the identification of viable myocardium, chiefly because of its feasibility, safety, diagnostic accuracy and prognostic power<sup>5</sup>. Low-dose dobutamine stress echocardiography (DSE) has emerged as an attractive and increasingly used method to identify viable myocardium through its ability to elicit a beta adrenoreceptor-mediated increase in myocardial contractility. Dobutamine-responsive wall motion was found to be specific for predicting reversible contractility dysfunction, but its sensitivity is lower than ideal<sup>6</sup>. In a prospective study design, we sought to explore the predictors of contractile recovery after revascularization, in patients with absence of viability by low-dose DSE.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Patient selection</bold>
      </p>
      <p>Prospectively, we enrolled 30 consecutive patients referred from our catheterization labs with significant coronary stenosis/occlusion, during the period from November 2006 to October 2008. Patients were considered eligible for inclusion if they had regional wall motion abnormality in the anatomical distribution of the affected arteries as explained later, affected arteries amenable for revascularization, and absence of viability by low-dose DSE. Significant coronary stenosis was defined as at least 70% luminal obstruction of at least one sizable coronary artery (measuring 2.5 mm or more in diameter), seen in 2 different projections. Total coronary occlusion was defined as 100% luminal obstruction with Thrombolysis In Myocardial Infarction (TIMI) grade 0 forward flow distal to the site of obstruction. We excluded patients with recent myocardial infarction or unstable angina during the past 4 weeks, significant stenosis of the left main coronary artery (defined as at least 50% luminal obstruction), decompensated heart failure, protruding fresh left ventricular thrombus, significant valvular or congenital heart disease, any myocardial disease apart from ischemia, left ventricular ejection fraction &gt; 40%, bundle branch block, contraindication to dobutamine (for example: history of complex ventricular arrhythmias, uncontrolled hypertension with blood pressure &gt; 180/110), and patients with limited life expectancy due to coexistent disease (for example: malignancy). Before inclusion, an informed written consent was obtained from each patient after full explanation of the study protocol, the type of data collected, the way of data processing and the scope of data collection. The study protocol was reviewed and approved by the local institutional human research committee in our center according to the ethical guidelines of the 1964 Declaration of Helsinki, as revised in 2002.</p>
      <p>
        <bold>Definitions of risk factors</bold>
      </p>
      <p>The presence of hypertension was defined as a systolic blood pressure <underline>&gt;</underline> 140 mmHg and/or a diastolic blood pressure <underline>&gt;</underline> 90 mmHg, previously recorded by repeated non-invasive office measurements, which lead to life-style modification or antihypertensive drug therapy. The presence of diabetes mellitus was defined as a fasting plasma glucose <underline>&gt;</underline> 126 mg/dl, and/or a 2-hour postload glucose <underline>&gt;</underline> 200 mg/dl, or specific anti-diabetic drug therapy. Dyslipidemia was defined by a low-density lipoprotein cholesterol &gt; 100 mg/dl, and/or serum triglycerides &gt; 150 mg/dl, and/or a high-density lipoprotein cholesterol &lt; 40 mg/dl in men and &lt; 50 mg/dl in women.</p>
      <p>
        <bold>Baseline echocardiographic assessment</bold>
      </p>
      <p>Assessment of regional and global left ventricular systolic function was performed in all patients by transthoracic echocardiography within 48 hours of admission. Doppler echocardiography was performed using a Hewlett Packard Sonos 5500 cardiac ultrasound machine (Hewlett Packard, Andover, Massachusetts, USA) equipped with harmonic imaging capabilities. A 2.5 MHz phased array probe was used to obtain standard 2D, M-mode and Doppler images. Patients were examined in the left lateral recumbent position using standard parasternal and apical views. Global left ventricular systolic function was assessed in apical 4-chamber and 2-chamber views using the biplane modified Simpson&#146;s method. Regional wall motion was assessed according to the standard 16-segment model recommended by the American Society of Echocardiography<sup>7</sup>. Individual segments were then sub-grouped based on the known vascular distribution into left anterior descending territory, left circumflex territory, right coronary artery territory, and overlap segments<sup>7</sup>. Regional wall motion was visually assessed for each segment individually, considering both endocardial excursion and systolic thickening, and each segment was graded according to the semiquantitative scoring system described by Knudsen et al<sup>8</sup>. Segments with poorly defined endocardial borders for 50% or more of their length were considered non-visualized and assigned a score of 0<sup>9</sup>. Wall thickening was assessed at a distance of at least 1 cm from the adjacent segment to minimize the effect of tethering<sup>10</sup>. Wall motion in a vascular territory was considered abnormal if wall thickening was abnormal in at least two contiguous non-overlap segments<sup>7</sup>. Wall motion score index (WMSI) was derived by dividing the sum of individual segment scores by the number of interpretable segments. </p>
      <p>
        <bold>Stress echocardiographic protocol</bold>
      </p>
      <p>All patients underwent low-dose DSE as follows: dobutamine (Dobutrex&#8482;, Lilly, Eli and Company, Indianapolis, USA) was infused intravenously starting at 5 &#181;g/kg/minute, increased up to 20 &#181;g/kg/minute, in 3-minute stages. Examinations were standardized and performed by the same operator. Standard views were recorded at baseline, during each stage of the infusion protocol, as well as during recovery. Images were digitized in cine-loop format and saved for subsequent playback and analysis. Views were analyzed by a single expert echocardiographist (Z.A.) employing the software program of the echocardiography machine. Analysis of viability was performed during all stages of the protocol. Visual assessment of wall motion and thickening was performed as before. Global left ventricular systolic function and wall motion score index were evaluated at rest and at the end of each stage. The presence of viability was defined by improvement in regional wall motion score by at least one grade in at least two contiguous non-overlap segments along with at least 20% reduction in global WMSI compared with baseline evaluation<sup>10</sup>. The stress test was performed with the patients on their full anti-ischemic and anti-failure medications. All patients were receiving beta-blockers, angiotensin converting enzyme inhibitors, statins and aspirin.</p>
      <p>
        <sup>
          <bold>99m</bold>
        </sup>
        <bold>Tc-sestamibi imaging protocol</bold>
      </p>
      <p>Patients underwent resting <sup>99m</sup>Tc-sestamibi imaging study with the administration of trimetazidine, using the standard imaging technique, within 4 days of coronary angiography, provided that no ischemic events were recorded during the time from the coronary angiography to <sup>99m</sup>Tc-sestamibi imaging. Trimetazidine (Vastarel&#8482;, Servier, France) was administered by the oral route the day before the study (60 mg divided in 3 equal doses 8 hours apart), and 1 hour before performing the study (60 mg in a single dose). Injection of 25-30 mCi of radioactive tracer was administered 45-60 minutes before image acquisition. Images were acquired using a rotating single-head gamma camera (GE Starcam 4000i, UK) equipped with low-energy all-purpose collimators. Energy windows of 20% were respectively centered on the 140-keV peaks of <sup>99m</sup>Tc-sestamibi. Thirty-two images were obtained over 180&#176; extending from the 45&#176; right anterior oblique to the 45&#176; left posterior oblique projections. All studies were subjected to quality-control checks and corrections when necessary for camera non-uniformity, center-of-rotation offsets, patient motion, and "upward creep"<sup>8</sup>.</p>
      <p>
        <sup>
          <bold>99m</bold>
        </sup>
        <bold>Tc-sestamibi image analysis</bold>
      </p>
      <p>Two experienced nuclear cardiologists blinded to the clinical, echocardiographic and angiographic data, analyzed the <sup>99m</sup>Tc-sestamibi images. The vascular assignment of myocardial segments to the vascular distribution of major coronary arteries was performed according to the 17 segments scoring system<sup>11</sup>. The percentage of <sup>99m</sup>Tc-sestamibi uptake was assessed for each segment individually. The mean value of percent <sup>99m</sup>Tc-sestamibi uptake was calculated for all left ventricular segments (total <sup>99m</sup>Tc-sestamibi uptake), as well as separately, for each individual vascular territory. </p>
      <p>
        <bold>Coronary revascularization</bold>
      </p>
      <p>All patients underwent coronary revascularization either by percutaneous coronary angioplasty, or by surgical bypass grafting according to the decision of the attending physician. Revascularization was performed within 2 weeks of the index coronary angiography, provided that no ischemic events were recorded during the time from the coronary angiography to revascularization. The decision was based on the clinical presentation, coronary anatomy and evidence of ischemia. </p>
      <p>
        <bold>Echocardiographic follow-up</bold>
      </p>
      <p>Follow-up echocardiographic re-assessment was performed 3 months after revascularization to evaluate regional and global left ventricular systolic function as described before. All evaluations were performed offline by the same echocardiographist (Z.A.) who was blinded to whether the images were obtained before or after revascularization. The occurrence of myocardial contractile recovery was defined by improvement in regional wall motion score by at least one grade in at least two contiguous non-overlap segments along with at least 20% reduction in global WMSI compared with baseline evaluation<sup>10</sup>. During follow-up, patients were questioned regarding the occurrence of new myocardial infarction or congestive heart failure by means of clinical visits, telephone calls, hospital chart reviews, or personal communication with the referring physician. </p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>All continuous variables were presented as mean &#177; SD, if they were normally distributed. Data were tested for normal distribution using the Kolmogorov-Smirnov test. Categorical variables were described with absolute and relative (percentage) frequencies. According to the above definition of myocardial contractile recovery, patients were classified into 2 groups: group 1 with evidence of actual myocardial contractile recovery after revascularization at follow-up echocardiography, and group 2 with no such evidence of recovery. The two groups were compared with respect to patients&#146; clinical characteristics, echocardiographic, scintigraphic and angiographic data, using the unpaired <italic>t</italic> test for normally distributed continuous variables, and the Pearson chi-square test for categorical variables. Multivariate regression analysis was performed to identify the independent predictors of myocardial contractile recovery after revascularization, in which the dependent variable was the outcome variable of interest, whereas factors entered into the model included the mean value of percent <sup>99m</sup>Tc-sestamibi uptake by all left ventricular segments (total <sup>99m</sup>Tc-sestamibi uptake), as well as that assessed separately, for each individual vascular territory, the mean resting left ventricular ejection fraction and WMSI before revascularization. Eventually, we generated a receiver-operating characteristics (ROCs) curve to identify the cutoff value of the percentage of total <sup>99m</sup>Tc-sestamibi uptake that best predicted myocardial contractile recovery after revascularization. The optimal cutoff value was defined as the value giving the largest area under the curve (AUC). Finally, twenty cases were randomly selected for analysis of intra-observer variability. Assessment of variability was performed using linear regression analysis. All analyses were 2-sided and a probability value of P &lt; 0.05 was considered statistically significant. Analyses were performed with the SPSS, version 12.0 statistical package (SPSS Inc., Chicago, IL, USA). </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Baseline demographic characteristics</bold>
      </p>
      <p>Of a total of 61 patients with significant coronary stenosis/occlusion amenable for revascularization and regional wall motion abnormality in the anatomical distribution of the affected arteries, during the study period, 31 had evidence of viability by low-dose DSE, while 30 had no such evidence of viability. All patients with positive viability by low-dose DSE underwent coronary revascularization. According to the aforementioned definition of myocardial contractile recovery at the 3-month follow-up echocardiography, there were 27 patients (87.1%) with evidence of myocardial contractile recovery after revascularization, and 4 (12.9%) with no such evidence of recovery. A total of 30 consecutive patients with no evidence of viability by low-dose DSE were included in the current study, who underwent coronary revascularization for significant coronary stenosis/occlusion. All patients completed the 3-month follow-up period, and no patient reported any clinical events during the period from revascularization to the follow-up echocardiography evaluation. According to the aforementioned definition of myocardial contractile recovery at follow-up echocardiography, there were 7 patients (23.3%) with evidence of myocardial contractile recovery after revascularization (group 1), and 23 (76.7%) with no such evidence of recovery (group 2). Of the total cohort (61 patients), low-dose DSE predicted myocardial contractile recovery following revascularization with a sensitivity of 79.4% and a specificity of 85.2%<sup>11</sup>.</p>
      <p>Revascularization was successful and complete in all patients. All patients in group 1 were revascularized by surgical bypass grafting, while in group 2, 5 patients (21.7%) were treated with percutaneous coronary angioplasty and 18 (78.3%) were treated by surgical bypass grafting (<italic>p</italic> &gt; 0.05). The demographic characteristics of the entire cohort as well as of the 2 individual groups are shown in <xref ref-type="table" rid="tab01-body3">Table 1</xref>. The mean age was 52.3 &#177; 5.9 years, with 97% of them being males. Diabetes mellitus was found more frequently in group 2 as compared to group 1 (69.6% <italic>versus</italic> 28.6% respectively, <italic>p</italic> &lt; 0.05). Otherwise, no statistically significant differences were found between the two groups regarding any of the demographic characteristics.</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt01-en.jpg"/></table-wrap>
      <p>
        <bold>Echocardiographic data</bold>
      </p>
      <p><xref ref-type="table" rid="tab02-body3">Table 2</xref> shows the DSE data of the entire study cohort as well as the 2 individual groups. At baseline, the mean left ventricular ejection fraction of the entire study cohort was 24 &#177; 4%, while the mean WMSI was 2.7 &#177; 0.15. No statistically significant differences were found between the two groups regarding any of the DSE data (<xref ref-type="table" rid="tab02-body3">Table 2</xref>). At the 6-month follow-up, the mean left ventricular ejection fraction was 30 &#177; 4% <italic>versus</italic> 24 &#177; 4%, while the mean WMSI was 2.3 &#177; 0.07 <italic>versus</italic> 2.6 &#177; 0.24, in group 1 as compared to group 2, respectively, (<italic>p</italic> &lt; 0.05 for both). </p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt02-en.jpg"/></table-wrap>
      <p>The DSE protocol was well tolerated by all patients with no major side effects during or after the test. </p>
      <p>
        <bold>Scintigraphic data</bold>
      </p>
      <p><xref ref-type="table" rid="tab03-body3">Table 3</xref> shows <sup>99m</sup>Tc-sestamibi scintigraphy data of the entire study cohort as well as of the 2 individual groups. The percentage of total <sup>99m</sup>Tc-sestamibi uptake was significantly higher in group 1 as compared to group 2 (78 &#177; 3% <italic>versus</italic> 64 &#177; 9% respectively, <italic>p</italic> &lt; 0.01). Similarly, the percentage of <sup>99m</sup>Tc-sestamibi uptake by segments in the left anterior descending coronary territory, was significantly higher in group 1 as compared to group 2 (90 &#177; 12% <italic>versus</italic> 78 &#177; 19% respectively, <italic>p</italic> &lt; 0.01). </p>
      <table-wrap id="tab03-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt03-en.jpg"/></table-wrap>
      <p>
        <bold>Independent predictors of contractile recovery</bold>
      </p>
      <p>The multivariate regression analysis showed that the percentage of total <sup>99m</sup>Tc-sestamibi uptake, and the uptake by segments in the left anterior descending coronary territory, independently predicted myocardial contractile recovery at 3-month follow-up after revascularization, with the former being the strongest independent predictor (<xref ref-type="table" rid="tab04-body3">Table 4</xref>).</p>
      <table-wrap id="tab04-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gt04-en.jpg"/></table-wrap>
      <p>
        <bold>Cutoff value for prediction of myocardial contractile recovery</bold>
      </p>
      <p>The receiver operating characteristics (ROCs) curve revealed that a cutoff value of the percentage of total <sup>99m</sup>Tc-sestamibi uptake of 72%, best predicted myocardial contractile recovery at 3 months following revascularization, with an area under the curve (AUC) =0.957 (95% confidence interval 0.812 to 0.994, <italic>p</italic> &lt; 0.001). Using this 72% cutoff value, the percentage of total <sup>99m</sup>Tc-sestamibi uptake had a sensitivity of 100%, specificity of 95.7%, for predicting myocardial contractile recovery following revascularization (<xref ref-type="fig" rid="fig01-body3">Figure 1</xref>).</p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-96-03-0188-00007-gf01-en.jpg"/></fig>
      <p>The analysis of intra-observer variability revealed a close correlation between repeated assessments of regional wall motion by the single operator, with a correlation coefficient r =0.92.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Assessment of myocardial viability is one of the most challenging areas of modern cardiology. The gold standard for the presence of viability is improvement in global and/or regional contractility following myocardial revascularization<sup>12</sup>. Nevertheless, triaging a patient for revascularization depends on the &#145;expected&#146; ensuing recovery of contractile function in the compromised area. In this regard, the ability of low-dose dobutamine to elicit a contractile response in dysfunctional, but viable myocardial segments supplied by occluded/critically stenosed arteries has been a controversial issue. Some previous studies reported the limited ability of even very low doses of dobutamine to unmask the presence of viable myocardium in the setting of severe coronary stenosis or total occlusion, where coronary flow reserve is exhausted and resting myocardial perfusion is severely reduced<sup>13</sup>. A meta-analysis of six studies (287 patients) that used DSE to predict improvement in the left ventricular systolic function following revascularization showed a weighted mean sensitivity and specificity of 57 and 73%, with a PPV and NPV of 63 and 68%, respectively<sup>14</sup>. </p>
      <p>Complex structural changes occur in viable dysfunctional myocardium at both cardiomyocyte and extracellular matrix levels<sup>15</sup>, which include ultrastructural abnormalities seen by electron microscopy<sup>16</sup>. Moreover, indirect markers of apoptosis have been recently demonstrated in more severely compromised hibernating cardiac myocytes<sup>17</sup>. Additionally, reduced gap junction area in hibernating myocardium might interfere with local coordination of myocyte contraction<sup>18</sup>. Other pathophysiological alterations in dysfunctional&#150;but viable&#150;myocardium include energy depletion<sup>19</sup> and reduced calcium responsiveness<sup>20</sup>. Overall, they may hamper the contractile response to low-dose dobutamine, with a subsequent large proportion of false negative results to DSE, and a resultant suboptimal sensitivity<sup>6</sup>. </p>
      <p>The issue of predicting myocardial contractile recovery following revascularization has long been controversial. Previously reported studies in literature have not provided consistent data to determine the specific predictors of potential contractile recovery. Some reports highlighted the importance of coronary collaterals to the infarct-related artery territory as a predictor of the presence of underlying myocardial viability and the potential myocardial contractile recovery following revascularization<sup>21,22</sup>. Generally speaking, it is always recommended to search for viable myocardium before revascularization of an occluded coronary artery; however, there is no practical, yet sensitive, method for assessing myocardial viability in the cath lab<sup>21</sup>. </p>
      <p>To the best of the authors&#146; knowledge, the current study was the first in literature to report that the percentage of total <sup>99m</sup>Tc-sestamibi uptake and the percentage of uptake by segments in the left anterior descending coronary territory, independently predicted &#145;actual&#146; myocardial contractile recovery at the 3-month follow-up following revascularization, in a very specific group of patients with absence of viability by low-dose DSE. Additionally, a cutoff value of 72%, of the former, predicted contractile recovery, with an excellent sensitivity and specificity. Nevertheless, the current study does not compare the two methods (low-dose DSE and <sup>99m</sup>Tc-sestamibi imaging) and an alleged superiority of <sup>99m</sup>Tc-sestamibi imaging over low-dose DSE cannot be advocated. Furthermore, even when resting systolic function does not recover following revascularization, the presence of partial viability is likely to be beneficial for contractile reserve, exercise tolerance, prevention of remodeling and survival; revascularization can still be beneficial in this group of patients<sup>23</sup>. </p>
      <p>In the current study, we employed a protocol of resting <sup>99m</sup>Tc-sestamibi imaging after oral administration of trimetazidine. A robust body of evidence indicates that resting <sup>99m</sup>Tc-sestamibi may be a good marker for viability<sup>24-26</sup>. Both trimetazidine and <sup>99m</sup>Tc-sestamibi share the same intracellular target: the mitochondrion. As metabolic reserve does exist in the hibernating state, trimetazidine might exploit this reserve by increasing mitochondrial metabolism. One study demonstrated that trimetazidine was associated with an increase in <sup>99m</sup>Tc-sestamibi uptake in infarcted, but viable myocardial areas and stated that this increase was probably related to improvement in mitochondrial oxidative metabolism, which is essential for <sup>99m</sup>Tc-sestamibi retention. They concluded that coupling trimetazidine administration to <sup>99m</sup>Tc-sestamibi perfusion scintigraphy may represent a better means of detecting viable myocardium<sup>27</sup>. </p>
      <p>Our results suggested that the absence of diabetes mellitus also predicted the presence of viability, though it was not an independent predictor at the multivariate regression analysis. A previous study by Auerbach et al<sup>28</sup> reported that, apart from anginal symptoms, no statistically significant association was found between the presence of viability (detected by positron emission tomography) and any of the clinical characteristics, including diabetes<sup>28</sup>. Inconsistent findings would reflect the heterogeneous nature of the underlying disease process, the lack of uniformity in patient selection and study protocols among different studies.</p>
      <p>
        <bold>Limitations of the study</bold>
      </p>
      <p>Our findings were based on a single-center study with a relatively small sample size, a fact that makes it difficult to generalize our results to all patients undergoing risk stratification for predicting contractile recovery after revascularization. Multicenter studies using the same protocol and examining a larger number of patients are needed. Additionally, the number of patients who recovered adequate contractility was very small; therefore the results of the current study should be considered with caution. Moreover, the follow-up period of 3 months might have been inadequate to allow recovery of some dyssynergic, but viable segments, which would otherwise translate to a better myocardial contractile recovery rate. Delayed recovery can further occur in a substantial number of segments up to a median of 14 months following revascularization, a fact that warrants repeated assessment after longer periods of follow-up. The fact that all patients were receiving beta blockers before DSE examination may have contributed to a substantial proportion of false negative results, since it is known that this drug interferes with the sensitivity of DSE. A possible limitation of the current study is that it does not provide a direct comparison between DSE and <sup>99m</sup>Tc-sestamibi perfusion scintigraphy. Given that magnetic resonance imaging is considered the gold standard for detection of viability, the fact that the patients did not undergo this modality may constitute another limitation. Another limitation of the study is the lack of quantitative methods for measuring systolic thickening; instead, the operator adopted visual assessment only. Nevertheless, the problem of intra-observer variability can be minimized by stronger adherence to common and new methodological standards. Finally, follow-up coronary angiography was not performed, therefore, restenosis or reocclusion cannot be definitely excluded, something that would hazard the initially achieved contractile recovery. However, no patient reported any clinical events during the period from revascularization to follow-up echocardiographic evaluation. </p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Our data suggest that myocardial contractile recovery after revascularization in patients with no evidence of viability by low-dose DSE could be independently predicted by the percentage of total <sup>99m</sup>Tc-sestamibi uptake and the uptake by segments in the left anterior descending coronary territory. A cutoff value of the percentage of total <sup>99m</sup>Tc-sestamibi uptake of 72% best predicted myocardial contractile recovery at 3 months following revascularization.</p>
      <p>
        <bold>Clinical implications</bold>
      </p>
      <p>Patients with ischemic left ventricular dysfunction whose coronary arteries are amenable for revascularization and who have no evidence of viability by low-dose DSE, may still have a "glimpse of hope" in gaining significant myocardial contractile recovery following revascularization, if they have an &#145;ample&#146; percentage of total left ventricular <sup>99m</sup>Tc-sestamibi uptake, especially in the absence of diabetes mellitus. The other way around is also true, however: due to the relatively low specificity of perfusion scintigraphy to detect viability, DSE can be performed in patients with positive viability by perfusion scintigraphy. Yet, the routine use of both modalities together in all patients cannot be advocated, as it would not be cost-effective.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
